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Abstract
During development the extracellular matrix is cleaved and remodeled to facilitate the
large-scale cell rearrangements that are necessary for processes like gastrulation, neurulation,
angiogenesis and organogenesis. ECM remodeling occurs primarily through secreted
enzymes called matrix metalloproteinases (MMPs). Regulation of MMP activity is achieved
through the tissue inhibitor of metalloproteinases (TIMPs), a small family of secreted
proteins that bind MMPs in a 1:1 manner to inhibit their activity. Although TIMPs were
originally characterized based on their MMP-inhibitory activities, in vitro studies have
revealed that TIMPs are multifunctional proteins, with structurally and functionally distinct
N- and C-terminal domains. TIMP N-terminal domains bind to and inhibit MMPs, whereas
their C-terminal domains have cell signaling activity in apoptosis, cell migration and cell
proliferation pathways. Using Xenopus laevis as a model organism, this study examined the
unique roles of the TIMP N- and C-terminal domains during development to investigate the
balance between TIMP MMP-inhibitory activity and signaling activity in vivo.
Microinjection was used to overexpress the three X. laevis TIMPs or their individual domains
in early stage embryos. This research demonstrated that the balance between MMPs and
inhibitors in the ECM is very important, and that the ECM functions as an intricate network.
Here I showed that the TIMP-1 and -2 C-terminal domains downregulated MMP
expression/activity within this network independent of MMP-inhibition. Additionally the
TIMP-1 and -2 C-domains altered signaling markers including caspase-3 and RECK, which
was not observed with N-domain constructs, and resulted in severe developmental defects. In
contrast, the TIMP-3 C-terminal domain performed no independent role in development.
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This research is the first comprehensive comparison of TIMP domain function in vivo, and
demonstrates for the first time a role for TIMP signaling during development.
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CHAPTER 1
GLOBAL INTRODUCTION AND LITERATURE REVIEW

2
1.1

The Extracellular Matrix
This work will examine the roles played by secreted enzymes and inhibitors that

regulate protein dynamics outside of cells. When one considers the myriad of functions
performed by the many tissues and organs within the body, these functions are often
attributed solely to cells. The tissues found in multicellular organisms, however, are not
composed exclusively of cells; rather, cells are embedded in an extracellular matrix (ECM)
that is essential for tissue and organ function. The ECM is a dynamic, complex network of
interacting macromolecules that both surrounds and structurally supports cells. As such, the
ECM is necessary for preserving tissue integrity in multicellular organisms. Additionally, the
bidirectional interactions that exist between cells and the ECM are important for coordinating
cellular functions. Communication with the ECM allows cells to perceive their changing
environment and adapt in an appropriate manner (Bissell, Hall et al. 1982). The nature,
regulation, and complexity of the exchanges between cells and the ECM are becoming
increasingly significant in the study of both development and disease. In this chapter, I will
begin by discussing the structural components of the ECM, and the roles of secreted enzymes
and their inhibitors in remodeling of the ECM. I will subsequently discuss the contributions
of these ECM remodeling proteins to the regulation of cancer progression, and most pertinent
to my research, embryonic development.

1.1.1. General structure of the ECM
One of the primary functions of the ECM is to provide the histoarchitecture necessary
for organ function and homeostasis (Aumailley and Gayraud 1998). Accordingly, the ECM is
composed predominantly of large structural proteins. The proteins that form the ECM are
secreted by cells embedded within the matrix, and are subsequently assembled into a
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precisely organized network that associates with cellular surfaces (Hays 1991). There are two
main structural classes of proteins that make up the ECM: proteoglycans and large fibrous
proteins. Proteoglycans are large hydrophilic molecules that consist of a protein core linked
to polysaccharide chains termed glycosaminoglycans (GAGs). Large fibrous proteins such as
collagen, elastin, fibronectin, and laminin are mainly structural in nature, although these
proteins also have crucial non-structural functions such as facilitating cell migration and cell
signaling. Variations in the arrangement and relative amounts of different ECM
macromolecules govern, and can also alter the character of, the ECM (Frantz, Stewart et al.
2010). In animal tissues, the ECM is found in two main forms: basement membrane (BM)
and stromal matrix. Basement membranes are thin layers of defined ECM molecules that
underlie epithelial cell sheets. The BM anchors the epithelium, serves as a barrier separating
epithelial cells from the underlying connective tissue, polarizes cells, and regulates cell
behavior (Nelson and Bissell 2006). In contrast, the stromal matrix contains abundant ECM
with comparatively few embedded cells, and is associated with connective tissues including
cartilage and bone. Stromal matrix is rich with proteoglycans, which form a hydrated gel-like
mesh due to their hydrophilic nature. Within this gel-like matrix are fibrous proteins such as
collagen and elastin, which provide strength to the stroma of tissues including tendons,
cartilage, skin, and artery walls (Frantz, Stewart et al. 2010).
It was originally thought that the ECM plays a passive role in mediating tissue and
organ function, acting only as a framework to provide structural support for tissues. We now
know that the ECM is exceedingly active, and interactions between cells and the ECM are
now recognized as important factors in the regulation of cell behavior. In all tissues, cells are
stably linked to the ECM. Although the composition of the ECM may vary from mainly
collagen II in cartilage and bone, to laminin and collagen IV in the BM of epithelia, cells are
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capable of sensing and responding to changes in the ECM. If the BM is removed from
epithelia, for example, the cells will either migrate or undergo apoptosis, depending on their
developmental fate. Furthermore, the organization of the ECM is both highly ordered and
varied, such that the ECM structure and composition is specifically altered and adapted to
serve the functional requirements of different tissues (Frantz, Stewart et al. 2010). For
instance, the ECM found in joints is important in maintaining hydration, in tendons the ECM
provides strength, in kidneys the ECM is involved in filtration, and in the embryo, the ECM
facilitates migration (reviewed in Frantz et al., 2010).

1.1.2.

The ECM facilitates cell migration via integrins and focal adhesion structures
Cell migration in tissues is dependent upon cell contact with the ECM. Cells cannot

migrate freely through extracellular space; rather, motility depends on the ability of a cell to
form adhesions with specific ECM substrates like fibronectin or laminin, which serve
functionally like roads for cell movement. Cells bind to ECM components through
transmembrane receptors on their plasma membranes. In animal cells, integrins are an
important family of ECM receptors, which are necessary for cell adhesion during migration.
Integrins are heterodimeric transmembrane proteins formed from association of α and β
polypeptide chains (Berrier and Yamada 2007). There are many different combinations of
possible α and β heterodimers, which impart binding specificity for different components of
the ECM (Luo, Carman et al. 2007). For instance, α5β1 binds fibronectin whereas α6β1 binds
laminin. When migrating cells adhere to the ECM, integrins link the cell cytoskeleton to
specific ECM substrates, forming a structure called a focal adhesion. Specific integrin-ECM
binding and focal adhesion formation initiate appropriate cellular signaling pathways to
facilitate cell motility. As the cell moves along its substrate, new focal adhesions are
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continuously being formed at the leading edge of the cell and released from the back of the
cell (Ridley, Schwartz et al. 2003). Therefore, the cell may recognize different ECM
components as suitable adhesive substrates, and the appropriate cell migration signaling
cascades are then initiated. This process is essential during development when large-scale
cell movements occur in a highly coordinated manner (Ridley, Schwartz et al. 2003).

1.1.3. The ECM as a regulator of cell signaling
In addition to its roles in mediating cell motility and providing structural integrity for
tissues, the ECM is also an important regulator of cell signaling in multicellular organisms.
heparan sulfate, a component of many proteoglycans, can bind to secreted growth factors in
the ECM, thereby transforming the matrix into a basin for biologically active molecules. The
association of growth factors with the ECM is important during embryogenesis, as growth
factors can be used to establish morphogenic gradients which pattern developmental events
(Hynes 2009). ECM proteoglycans bind to a variety of signaling molecules and growth
factors including fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF),
and transforming growth factor-β (TGF-β) (Shi and Massague 2003; Mohammadi, Olsen et
al. 2005). Cleavage of ECM proteins or of the GAGs associated with ECM proteoglycans
releases these signaling factors (discussed further in sections 1.6 and 1.7), which can
subsequently affect cell behavior, leading to changes in migration, proliferation, and survival
(Hynes 2009).
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1.2

Matrix Metalloproteinases

1.2.1. Structure and function of MMPs
Matrix metalloproteinases (MMPs) are a family of 25 secreted zinc-dependent
endopeptidases. The primary function of MMPs is to facilitate cleavage and remodeling of
the ECM through selective degradation of ECM components (Vu and Werb 2000).
Traditionally, MMPs have been classified into four groups on the basis of their substrate
specificity for particular ECM components: collagenases, gelatinases, stromelysins and
matrilysins. As the list of MMP substrates has become longer and more complex, however, it
is now more common to classify MMPs into two distinct groups based on their structure and
localization: membrane-type MMPs (MT-MMPs), which are anchored to the cell surface,
and secreted MMPs, which are soluble in the ECM (Egeblad and Werb 2002).
Although MMP localization and substrate specificity may vary, most MMPs contain
several conserved domains, which are essential for their structure and function. Generally,
MMPs contain a cleaved N-terminal signal sequence used for secretion, an N-terminal
propeptide (PRO) domain that regulates activity, a catalytic Zn2+-binding domain that
contains the MMP catalytic site, a linker domain (also called the hinge region), and a
hemopexin (HPX) domain that mediates interactions with target proteins (Nagase, Visse et
al. 2006). All MMPs are synthesized as inactive proenzymes, and become activated after the
removal of their PRO domain. The PRO domain inhibits MMP activity through interaction of
a cysteine residue in the PRO domain with the zinc moiety in the MMP catalytic site
(Nagase, Visse et al. 2006). Most secreted MMPs are activated in the ECM by other active
MMPs or serine proteases; whereas, the MT-MMPs are cleaved intracellularly in the Golgi
by furin-like serine proteases and inserted into the plasma membrane in their active form
(Sternlicht and Werb 2001).
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1.2.2. Membrane-type MMPs
Membrane-type MMPs are a particularly unique class of metalloproteinase. Unlike
secreted MMPs which are activated extracellularly and may diffuse freely throughout the
ECM, MT-MMPs are activated intracellularly and immobilized in the plasma membrane,
thus, the activites of the MT-MMPs are limited to the surface of the cells that produced them
(Seiki 2002). There are six MT-MMPs that have been identified: MT4- and MT6-MMP are
anchored to the cell surface via a glycosylphosphatidylinositol (GPI) anchor; whereas, MT1-,
MT2-, MT3- and MT5-MMP are type I transmembrane proteins, containing a single
transmembrane domain and short cytosolic C-terminal domain (Seiki 2002). The presence of
a C-terminal domain is distinctive to this subset of MT-MMPs and plays an important role in
regulating cellular localization and turnover of these proteins (Wang, Ma et al. 2004).

1.2.3. MT1-MMP
Of the six MT-MMPs, MT1-MMP (also known as MMP-14) was the first identified,
and is also the best characterized. MT1-MMP can digest a number of cell surface
components (CD44, cadherin) and ECM proteins, including type IV collagen, and is a key
regulator of cellular invasion in development and disease. The cytosolic C-terminal tail of
MT1-MMP is important in regulation of invasiveness, as deletion of this domain decreased
the invasion-promoting activity of MT1-MMP in human melanoma cells (Lehti, Valtanen et
al. 2000). Additionally, the C-terminal domain of MT1-MMP has been linked to enhanced
cell migration by facilitating localization of MT1-MMP to invadopodia, and has also been
linked to internalization and turnover of the enzyme with respect to its presence on the
membrane, highlighting the importance of this domain in regulating MT1-MMP function
(Nakahara, Howard et al. 1997; Jiang, Lehti et al. 2001; Uekita, Itoh et al. 2001). As well as
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cleaving known ECM substrates, MT1-MMP is involved in the activation of pro-MMP-2
(see section 1.2.4.), which further augments the migratory potential of MT1-MMP expressing
cells (Itoh, Takamura et al. 2001). Upregulation of MT1-MMP is often associated with
pathological conditions including cancer, partly due to its direct role in facilitating cell
migration and invasion, and partly due to its role in activating pro-MMP-2, which is a very
robust ECM protease. Not surprisingly, MT1-MMP also plays an important role in
development. Of the many MMP knockout mouse models, only the MT1-MMP null mutant
is lethal, resulting in death by 3 weeks of age due to severe skeletal and vascularization
defects (Zhou, Apte et al. 2000).

1.2.4. The gelatinases
The gelatinases MMP-2 (gelatinase A) and MMP-9 (gelatinase B) are considered two
potent ECM proteases primarily because of their ability to cleave type IV collagen, which is
an abundant component of BMs (Khasigov, Podobed et al. 2003). MMP-2 and -9 have
important functional roles in vivo, particularly during development, as cleavage of BM
components is important in facilitating cell migration and differentiation (Werb, Ashkenas et
al. 1996; Carinato, Walter et al. 2000). During mouse development, MMP-9 expression is
detected in the liver, the endochondral plates of developing bone, neural cells, and
developing respiratory structures including the bronchial epithelium of the lungs and the
developing alveoli (Canete-Soler, Gui et al. 1995). In contrast, MMP-2 expression is detected
mainly in mesenchymal tissues and organs such as kidney and lung (Reponen, Sahlberg et al.
1992). Further studies using avian embryos have shown that MMP-2 expression is required in
neural crest cells to facilitate an epithelial to mesenchymal transition (EMT), where the
neural crest cells detach from the neural epithelium and migrate away from the neural tube
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(Duong and Erickson 2004). As mentioned above, MT1-MMP is involved in direct activation
of pro-MMP-2. Active MMP-2 can in turn cleave and activate pro-MMP-9, thus, the
gelatinases function as part of a powerful axis that controls degradation of ECM components
(Toth, Chvyrkova et al. 2003). As such, upregulation in the activities of these MMPs are
frequently associated with disease. MMP-2 and -9 play a significant role in cancer metastasis
and facilitate EMT through cleavage of the BM, which leads to cell invasion (Khasigov,
Podobed et al. 2003). Accordingly, MMP activity must be tightly regulated in a controlled
manner to maintain normal tissue homeostasis both during development and in adults.

1.3 Tissue Inhibitors of Metalloproteinases
The tissue inhibitors of metalloproteinases (TIMPs) are endogenous MMP inhibitors,
which play important roles in regulating MMP activity in vivo. In vertebrates, four TIMPs
have been identified (TIMP 1-4). TIMP orthologs are found in many species throughout the
animal kingdom including worms and insects, indicating the importance of this ancient
protein family (Murphy 2011). Together, the four vertebrate TIMPs have the ability to inhibit
all known MMPs (Visse and Nagase 2003). As TIMPs exhibit functional redundancy,
orthologs of each TIMP are not expressed in all vertebrates; however, mammals express all
four TIMPs (Murphy 2011).
TIMP genes are regulated at the transcriptional level through cytokine and growth
factor signaling, and the expression patterns of the individual TIMPs are variable. While
TIMP-2 tends to be constitutively expressed, the other TIMPs show more tissue-specific
expression patterns (Murphy 2011). Most notably, TIMP-1 is highly expressed in
reproductive organs and the central nervous system, particularly in regions of neuronal
plasticity such as the hippocampus and cerebellum. In contrast, TIMP-3 expression is often
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associated with the BMs of the eye and kidney (Murphy 2011). Although there is functional
redundancy in many of the MMP-inhibitory activities of the four TIMPs, there are subtle
differences in their inhibitory abilities. For instance, TIMP-3 is unique with respect to the
other TIMPs due to its ability to strongly inhibit members of the A Disintegrin and
Metalloproteinase (ADAM) family proteases, including ADAM-17 (also known as TACE;
Tumor necrosis factor-α converting enzyme) (Amour, Slocombe et al. 1998).

1.3.1. TIMP domain structure and function
TIMPs are small secreted proteins found within the ECM, where after removal of an
N-terminal signal sequence, the mature TIMP proteins generally consist of between 184 –
194 amino acids. The individual TIMP family members each have similar tertiary structure,
and can be divided into distinct N- and C-terminal domains (Nagase, Visse et al. 2006). As a
group, the mammalian TIMPs share 35-50% sequence similarity at the amino acid level, and
there are specific structural features that are highly conserved amongst all TIMPs. Most
importantly, all TIMPs contain 12 conserved cysteine resides which form 6 intramolecular
disulfide bonds (Murate and Hayakawa 1999). The positions of the 12 cysteine residues and
the subsequent formation of the disulfide bonds are crucial for the proper folding of all TIMP
proteins into a looped structure, which delineates and stabilizes the conformations of the Nand C-terminal domains. The first 6 cysteine residues form 3 loops that comprise the TIMP
N-terminal domains. Likewise, the latter 6 cysteine residues form 3 C-terminal domain loops
(Figure 1.1) (Murate and Hayakawa 1999). The two TIMP domains are structurally and
functionally distinct, and have been shown to fold and function independently in vitro (Brew
and Nagase 2010; Bahudhanapati, Zhang et al. 2011).
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The primary role of TIMPs is to inhibit MMP enzymatic activity, thereby regulating
cleavage and degradation of ECM components. The TIMP N-terminal domains are
responsible for direct inhibition of MMP activity via binding to the MMP active site in a 1:1
manner, chelating the Zn2+ ion in the MMP active site, and effectively blocking MMP
catalytic activity (Nagase, Visse et al. 2006). Although it was originally believed that the sole
function of TIMPs was to attenuate the action of MMPs, it is now known that the TIMP Cterminal domains have MMP-independent functions and can influence cell behavior through
direct regulation of a number of cell signaling pathways (Chirco, Liu et al. 2006). The Cterminal domains of the various TIMPs have been linked to cell growth, migration, and
apoptosis pathways (Guedez, Stetler-Stevenson et al. 1998; Wang, Yamashita et al. 2002;
Oh, Seo et al. 2004). To date, however, much of the work characterizing TIMP domain
function has been carried out in vitro. Although some cell surface binding partners and
signaling events associated with the TIMP C-terminal domains have been identified,
activation of specific signaling pathways in vitro varies with TIMP and cell type (discussed
further in section 1.6.2.) (Bourboulia and Stetler-Stevenson 2010). Currently, comparatively
little research has been done characterizing TIMP domain function in vivo.
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Figure 1.1. General schematic secondary structure of TIMP proteins. Mature TIMP
proteins contain 12 conserved cysteines (numbered in blue). The 6 N-terminal cysteine
residues (red) form 3 disulfide bonds, which result in 3 loops that comprise the N-terminal
domains (dashed line; loop 1-3). The 6 C-terminal cysteine residues (purple) form 3 disulfide
bonds, which result in 3 loops that comprise the C-terminal domains (dotted line; loop 4-6).
The arrow indicates the short boundary region between N- and C-terminal domains. Based on
(Murate and Hayakawa 1999).
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1.4 Reversion-inducing Cysteine-rich Protein with Kazal Motifs
In addition to TIMPs, REversion-inducing Cysteine-rich protein with Kazal motifs
(RECK) is another important regulator of MMP activity in both development and disease.
RECK is a cell surface MMP inhibitor that contains three serine protease inhibitor-like
domains (termed Kazal motifs) and is bound to the plasma membrane via a GPI anchor at its
carboxy terminus (Takahashi, Sheng et al. 1998). The RECK gene was first isolated from a
ras-transformed mouse fibroblast cell line (NIH3T3 cells). Due to its MMP-inhibitory
activity, RECK has since been identified as an important tumor suppressor protein with antiinvasive properties (Takahashi, Sheng et al. 1998). While RECK is expressed in many normal
adult tissues, its expression is often undetectable in tumor cell lines. Moreover, RECK has
been shown to be down-regulated in response to various oncogenes, including ras
(Takahashi, Sheng et al. 1998; Sasahara, Takahashi et al. 1999).
In addition to its role as a tumor suppressor, RECK is also important in regulating
developmental events. During development, RECK expression is high in cells that make up
the developing blood vessels and low in the surrounding tissues (Oh, Takahashi et al. 2001).
Studies using mice have shown that RECK-deficient embryos have impaired formation of the
vasculature (Oh, Takahashi et al. 2001). Vascular development is highly reliant on cell
migration and ECM remodeling mediated by active MMPs, however, excessive MMP
activity can also be detrimental during this process, and thus, must be tightly controlled. As
RECK is known to be a good inhibitor of potent MMPs including MMP-2, MMP-9 and
MT1-MMP, inhibition of MMP activity by RECK is essential during vascularization
(Takahashi, Sheng et al. 1998; Oh, Takahashi et al. 2001). Taken together, the action of
MMP inhibitors like RECK and TIMPs balanced with the action of active MMPs is
extremely important in regulating ECM remodeling events in development and in disease.
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1.5 Regulation of the ECM Proteolytic Network

To achieve and maintain homeostasis, the activities of MMPs, TIMPs, and RECK
must be tightly controlled and constantly adjusted. In combination with the balance between
secreted MMP and TIMP levels in the ECM, regulation of cell surface proteases and
inhibitors like MT1-MMP and RECK, together play important roles in controlling the
function, migration, and invasiveness of cells (Bourboulia and Stetler-Stevenson 2010). In
addition to maintaining the appropriate balance between the activities of ECM proteases and
inhibitors, the individual contributions of the TIMP N- and C-terminal domains must also be
balanced with respect to the relative abundance of their appropriate binding partners in the
ECM and on the cell surface. Whereas the TIMP N-terminal domains bind to MMPs in the
ECM, the C-terminal domains can also influence cell behavior by signaling through cell
surface receptors. As we learn more about the ECM and the proteins within it, it is evident
that regulation of the ECM proteolytic network is exceedingly complex. As a result,
increasing research has focused on the relative levels of, and interactions between,
extracellular and cell surface proteins. It is now clear that MMPs and TIMPs are not only
important in regulating ECM turnover, but that MMP non-proteolytic and TIMP noninhibitory domains also play important roles in regulating ECM dynamics and cell behavior.
In this section I will discuss some of the complex interactions between MMPs and TIMPs,
and the ways in which TIMPs can regulate ECM dynamics, aside from direct inhibition of
MMP activity.

1.5.1. TIMP-2 mediated activation of pro-MMP-2
TIMPs are important multifunctional proteins that can influence cell behavior,
through several different mechanisms. As previously mentioned, TIMP N-terminal domains
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are known to inhibit MMP activity, and TIMP C-terminal domains have been associated with
various cell surface receptors and signaling pathways, however, TIMPs can also interact with
cell surface MMPs or receptors to modulate the expression and activity of other proteins. An
important example of such an interaction is the association between MT1-MMP, TIMP-2,
and pro-MMP-2 (Seiki 2002). Active MT1-MMP on the cell surface (primarily on migratory
cells), can bind to pro-MMP-2 and TIMP-2 in a complex that ultimately results in the
activation of pro-MMP-2. In this complex, two molecules of MT1-MMP are required in
close proximity on the cell surface (Itoh, Takamura et al. 2001). One molecule of MT1-MMP
serves as a receptor for TIMP-2 and pro-MMP-2. The C-terminal domain of TIMP-2 binds to
the HPX domain of pro-MMP-2, while its N-terminal domain binds to and inhibits the
catalytic domain of MT1-MMP. Thus, TIMP-2 is required for the appropriate positioning of
pro-MMP-2, and serves as an adaptor between MT1-MMP and pro-MMP-2 in this complex.
A second MT1-MMP then cleaves the PRO domain of the appropriately positioned proMMP-2 resulting in its activation (Figure 1.2) (Itoh, Takamura et al. 2001). Relative
stoichiometry between the levels of MMPs, TIMPs, and cell surface receptors may have an
important impact on the formation of this complex. For instance, low levels of TIMP-2
facilitate activation of pro-MMP-2, however, higher levels of TIMP-2 saturate and inhibit
available MT1-MMP receptors, thereby preventing pro-MMP-2 activation (Romi, Helgeland
et al. 2012). As MT1-MMP/TIMP-2 mediated activation of pro-MMP-2 is known to
dramatically increase the migratory and invasive potential of cells, the stoichiometry needed
for the proper formation of this complex is important during both development and cancer
progression (Itoh, Takamura et al. 2001).
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1.5.2. Regulation of pro-MMP-9 in the ECM
Activation of pro-MMP-9 is another important determinant in regulating cell
migration and invasion. Similar to pro-MMP-2 activation, extracellular cleavage of proMMP-9 involves complex interactions between a variety of ECM and cell surface proteins.
In cancer cells, pro-MMP-9 activation contributes to an invasive phenotype, and pro-MMP-9
is activated by MMP-2. The cell surface protein CD44 acts as a binding partner to position
pro-MMP-9 for activation. CD44 and pro-MMP-9 co-localize to invadopodia where active
MMP-2 can subsequently cleave and activate pro-MMP-9 (Figure 1.2) (Bourguignon, GunjaSmith et al. 1998; Murphy, Stanton et al. 1999). As MT1-MMP activates pro-MMP-2, MT1MMP, therefore, also plays an important role in facilitating the downstream activation of proMMP-9.
Additionally, pro-MMP-9 is known to form a complex with TIMP-1 in the ECM
(Goldberg, Strongin et al. 1992). This interaction occurs through the C-terminal domain of
TIMP-1, where the N-terminal domain remains available for MMP inhibition (Itoh and
Nagase 1995). Intracellular co-localization of TIMP-1 with pro-MMP-9 has also been
detected in the Golgi, and many cells secrete pro-MMP-9 and TIMP-1 together (Roderfeld,
Graf et al. 2007). Although the functional significance of this complex remains unknown, it
has been suggested that association of pro-MMP-9 with TIMP-1 may be required for
stabilization of the zymogen (inactive pro-enzyme) and regulation of proteolytic activity.
Collectively, these studies with MMP-2 and -9 highlight the complexity of the interactions
between various ECM molecules as well as the importance of the non-inhibitory TIMP
domains in regulating the ECM proteolytic network.
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1.5.3. TIMP-2 mediated upregulation of RECK
In addition to their direct roles in regulating the activities of ECM proteins, TIMPs
may also influence the proteolytic network indirectly through C-terminal domain-mediated
activation of cell signaling pathways. TIMP-2 is perhaps the most well studied member of
the TIMP family, and its MMP-independent functions have been well characterized, at least
in vitro. In human endothelial cells, TIMP-2 has been linked to a specific signaling pathway,
which ultimately results in upregulation in RECK expression and decreased cell migration
(Oh, Seo et al. 2004). A series of elegant experiments have demonstrated that TIMP-2mediated upregulation in RECK expression is independent of its N-terminal MMP-inhibitory
domain, and occurs through binding of the TIMP-2 C-terminal domain to α3β1 integrin
receptors on the cell surface (Seo, Li et al. 2003; Seo, Li et al. 2006). Along with coimmunoprecipitation of α3β1 integrins using TIMP-2 antibodies, competitive binding studies
using antibodies that block the α3 and β1 integrin subunits have shown that TIMP-2 binding
is specific to α3β1 integrin receptors on human microvascular endothelial cells (Seo, Li et al.
2003). By the addition of a single alanine residue to the N-terminal domain of TIMP-2
(ALA+TIMP-2), the N-terminal domain MMP-inhibitory activity is disrupted, leaving only a
functional C-terminal domain (Wingfield, Sax et al. 1999). Both TIMP-2 and ALA+TIMP-2
were shown to bind to α3β1 integrins leading to upregulation in RECK RNA and RECK
protein (Figure 1.2) (Oh, Diaz et al. 2006; Seo, Li et al. 2006). As RECK is a cell surface
inhibitor of MT1-MMP, MMP-2, and MMP-9, increased RECK expression resulted in
decreased endothelial cell migration (Oh, Seo et al. 2004; Oh, Diaz et al. 2006).
Thus, in addition to direct inhibition of MMP activity by its N-terminal domain,
TIMP-2 may function to indirectly inhibit MMP activity through C-terminal domainmediated upregulation of RECK. With the added contradictory ability of TIMP-2 to activate
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pro-MMP-2 in association with MT1-MMP, regulation of this important ECM molecule is
essential for maintiaing homeostasis in the ECM. Given the complexity involved in the
regulation of TIMP-2 activities alone, when examined in concert with the varied activities of
the other TIMPs and MMPs, it is evident that disruptions to the intricate dynamics of the
ECM proteolytic network may have negative consequences for the organism as a whole.
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Figure 1.2. Cell surface regulation of the ECM proteolytic network. From left to right,
pro-MMP-9 binds CD44 on the cell membrane where it is activated by MMP-2. TIMP-2
complexes with MT1-MMP and pro-MMP-2 to mediate cleavage and activation of proMMP-2 by a second molecule of MT1-MMP. The TIMP-2 C-terminal domain binds to α3β1
integrins on the cell surface leading to upregulation in the cell surface MMP inhibitor,
RECK. RECK subsequently inhibits the activity of MT1-MMP, MMP-2, and MMP-9.
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1.6 Functions of the ECM Proteolytic Network in Cancer
1.6.1. The role of MMPs in cancer and metastasis
For many years it has been known that upregulation of MMP levels and activities are
detrimental to normal tissue function. Although MMPs are highly active during development
when many cell migration and ECM remodeling events occur, their activities must still be
tightly regulated at this time. In contrast, MMP expression is limited in most adult tissues and
elevated MMP activity is associated mainly with controlled remodeling events such as
wound healing (Ma, Tarnuzzer et al. 1999). In adult tissues, increases in MMP activity are
associated with pathological conditions, most commonly cancer.
MMPs have been implicated as positive regulators of cancer progression from the
early stages of tumor growth to later stages of invasion and metastasis (Mandal, Mandal et al.
2003). In early stages, cleavage of the ECM or BM components by MMPs contributes to the
formation of a microenvironment that promotes tumorigenesis. The tumor microenvironment
is a combination of tumor cells, stromal cells, growth factors and ECM constituents. Within
the past decade, the tumor microenvironment has become recognized as an important
regulator of tumor behavior (Bhowmick, Neilson et al. 2004; Littlepage, Egeblad et al. 2005).
MMPs are secreted by tumor cells and tumor-associated fibroblasts, and the roles of active
MMPs within the microenvironment are varied. Through direct cleavage of the structural
ECM molecules collagen IV and laminin 5, MMPs expose cryptic sites on these proteins that
foster tumor cell growth and angiogenesis (Xu, Rodriguez et al. 2001). Additionally, many
cytokines and growth factors are sequestered within the ECM. Degradation of the ECM may
facilitate release of growth factors, and further direct cleavage of latent growth factors by
MMPs may facilitate their activation. Release of and/or activation of growth factors in the
ECM significantly contributes to tumor progression by enhancing tumor cell growth,
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angiogenesis, and tumor cell migration (Bourboulia and Stetler-Stevenson 2010). For
instance, MMP-9 can release VEGF from the ECM, leading to increased angiogenesis
(Bergers, Brekken et al. 2000). Similarly, insulin-like growth factors (IGFs) and TGF-β are
important targets of MMP activity in tumors. MMPs cleave IGF binding proteins, permitting
release of IGFs and binding of IGFs to their receptors, which results in enhanced tumor cell
growth (Bergers, Brekken et al. 2000). Additionally, MMP-2 and -9 specifically, can release
and activate fibronectin-bound TGF-β, which induces EMT and promotes tumor cell
proliferation (Yu and Stamenkovic 2000).
As well as triggering tumorigenesis, MMPs also contribute to later stages of tumor
progression by facilitating cell migration and invasion, which are important factors that
contribute to metastasis. This can occur through targeted cleavage of BM or ECM
components, or by cleavage of cell-cell adhesion molecules. For instance, degradation of the
strcutural ECM molecule laminin 5 by MT1-MMP leads directly to tumor cell migration;
whereas, cleavage of membrane-bound E-cadherin by MMP-3 (stromelysin-1) and MMP-7
(matrilysin) results in disruption of cell contacts leading to cell dissociation, which promotes
invasion (Koshikawa, Giannelli et al. 2000; Noe, Fingleton et al. 2001).
In summary, MMPs can contribute to cancer progression through many mechanisms,
such as cytokine release or activation, which are not necessarily strictly related to proteolytic
cleavage of ECM structural molecules. Additionally, MMPs positively regulate processes
including tumor cell growth, angiogenesis, migration, and invasion, demonstrating the
significance of these molecules in regulating the tumor microenvironment. Given the many
roles of MMPs in cancer, it is evident that regulation of MMP activity is critical for
prevention of disease and for maintenance of normal tissue integrity.
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1.6.2. The role of TIMPs in cancer
Taking into consideration the importance of MMP activity in tumor progression,
some anti-cancer therapies have focused on sequestering MMP activity as a means of
treatment. As all four TIMPs are naturally occurring MMP inhibitors, it was originally
thought that TIMPs might act as an intrinsic guard against tumor progression (StetlerStevenson 2008). Accordingly, synthetic MMP inhibitors were designed to mimic the Nterminal MMP-inhibitory activities of TIMPs, however, these drugs failed as anti-cancer
therapies in clinical trials (Brown 1998; Coussens, Fingleton et al. 2002). It is now broadly
acknowledged that while TIMPs do have some anti-tumorigenic properties, TIMPs play a
dual role in the regulation of tumorigenesis. Though TIMPs were originally characterized
based on their ability to inhibit MMP activity, the importance of the additional biological
activities mediated by the TIMP C-terminal domains is now widely recognized. Through
their C-terminal domains, TIMPs can influence a variety of cell signaling pathways including
cell growth, migration, and apoptosis. These MMP-independent functions may have
significant implications for the progression and treatment of disease (Stetler-Stevenson
2008).
Both TIMP-1 and -2 have been shown to have cell growth promoting activity in a
variety of cancer cell lines (Stetler-Stevenson, 2008). The cell growth promoting abilities of
TIMP-1 and -2 were demonstrated through their ability to induce increased uptake of [3H]
thymidine in several tumorigenic cell lines. This activity is specific to the TIMP C-terminal
domains, as reductive alkylation, which renders TIMP N-terminal domains devoid of MMPinhibitory activity, did not abolish the growth promoting abilities of TIMP-1 and -2
(Hayakawa, Yamashita et al. 1992; Hayakawa, Yamashita et al. 1994). It has been suggested
that TIMP-1 and -2 may enhance cell growth through ras-dependent pathways, as research
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using an osteosarcoma cell line showed that both TIMP-1 and -2 increased the levels of GTPbound (active) ras in a dose-dependent manner (Wang, Yamashita et al. 2002). A more recent
study showed that TIMP-2 binding to MT1-MMP on the surface of MCF-7 breast cancer
cells might stimulate tumor cell growth through activation of the mitogen-activated protein
kinase (MAPK) pathway (D'Alessio, Ferrari et al. 2008). This study also demonstrated that
the TIMP-2 cell growth promoting activities are dependent on its C-terminal cell signaling
domain, as both TIMP-2 and ALA+TIMP-2 were able to activate MAPK (Figure 1.3).
Moreover, this work implicates an important role for the C-terminal domain of MT1-MMP in
cell signaling, as MT1-MMP mutants devoid of a cytosolic domain were unable to transmit
the signal (D'Alessio, Ferrari et al. 2008).
Although specific cell growth promoting pathways for TIMP-1 have not been as well
characterized, TIMP-1 has also been linked to inhibition of apoptosis in various cancer cell
lines. In Burkitt’s lymphoma cell lines, both TIMP-1 and alkylated TIMP-1 devoid of MMPinhibitory activity suppressed apoptosis. TIMP-1 was associated with reduced activity of
caspase-3 as well as an increase in the survival factor Bcl-XL (Guedez, Stetler-Stevenson et
al. 1998). In MCF10A human breast epithelial cells, TIMP-1 has also been shown to
suppress anoikis, which is a form of programmed cell death initiated by loss of cell adhesion
(Li, Fridman et al. 1999). More recent research has identified CD63, a member of the
tetraspanin family, as a cell surface binding partner for TIMP-1 in MCF10A cells. TIMP-1
has been shown to form a complex with CD63 and β1 integrin on the cell surface (Figure
1.3). Formation of this complex mediates the anti-apoptotic properties of TIMP-1, as downregulation of CD63 using short-hairpin RNA restored the cell’s ability to undergo apoptosis
(Berditchevski and Odintsova 1999; Jung, Liu et al. 2006). TIMP-3 has also been associated
apoptosis, and has been linked to both induction and inhibition of apoptosis, depending on
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the model system used. Unlike TIMP-1, however, there is currently limited data to support
the notion that TIMP-3 may directly participate in cell signaling. Rather, it has been
suggested that TIMP-3 may indirectly influence cell behavior through modulation of MMP
and ADAM activity, which in turn can alter the availablity of signaling molecules within the
ECM (reviewed in Stetler-Stevenson, 2008). Both the cell growth promoting and antiapoptotic activities of TIMPs demonstrate that TIMPs are multifunctional proteins that may
contribute to cancer progression through many different mechanisms.
In contrast to TIMP-1, which is upregulated in many cancers and has generally been
associated with negative prognosis, TIMP-2 has varying effects on tumor progression and
may also exhibit anti-tumorigenic properties through its C-terminal cell signaling domain in
addition to its MMP-inhibitory activities (reviewed in Stetler-Stevson, 2008). This is
highlighted through research by Oh et al. (2004), which showed that TIMP-2 and
ALA+TIMP-2 binding to α3β1 integrins on the surface of human microvascular endothelial
cells initiated a signaling cascade that resulted in increased expression of RECK and
subsequently decreased cell migration (Figure 1.3, and discussed in section 1.5.3.).
Interestingly, association of TIMP-2 with α3β1 integrins also resulted in cell growth arrest in
G1 phase of the cell cycle through increased de novo expression of the cyclin-dependent
kinase inhibitor p27Kip1 (Figure 1.3) (Seo, Li et al. 2006). Thus, TIMP-2 may act to either
promote or inhibit cell growth in different cell lines in vitro.
Taken together, these studies highlight the fact that TIMP activities are both cell type
and context dependent. Added to the complexity, TIMP function also depends on the relative
stoichiometry of matrix and signaling molecules within the ECM and on the cell surface. For
instance, the presence of MMP-9 may alter the signaling activity of TIMP-1 through CD63
receptors. MMP-9 can compete with CD63 for binding of TIMP-1, thus reducing or

25
abolishing the anti-apoptotic activity of TIMP-1 in complex with CD63 on the cell surface
(Chirco, Liu et al. 2006). As most of the research characterizing TIMP domain function has
been carried out in vitro under controlled conditions, where many ECM interactions are
limited, the roles of the TIMP C-terminal domains in cell signaling seem to vary with cell
type. Accordingly, there is a need to further examine the roles of TIMPs in vivo, where the
complexity of the ECM in the whole organism may influence TIMP function, particularly
with respect to the availability of the TIMP C-terminal domains to participate in cell
signaling events.
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Figure 1.3. Regulation of cell signaling by TIMP-1 and TIMP-2 at the cell surface. From
left to right, TIMP-1 binds to β1 integrin and CD63 through its C-terminal domain to initiate
a signaling cascade that results in inhibition of apoptosis. The C-terminal domain of TIMP-2
binds to MT1-MMP to initiate MAPK signaling. The TIMP-2 C-terminal domain binds to
α3β1 integrins leading to p27Kip1-mediated inhibition of cell growth and upregulation of the
membrane bound MMP inhibitor RECK.
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1.7 The role of the ECM Proteolytic Network in Regulating Development
While the MMP/TIMP balance must be tightly regulated in normal adult tissues to
prevent tumorigenesis, both MMPs and their inhibitors are highly expressed during
development to permit ECM proteolysis and remodeling. Indeed, many of the same processes
that are upregulated during tumor progression are also required for the progression of normal
development. Cell migration, cell invasion, and angiogenesis are important developmental
processes required for tissue morphogenesis and organ formation. Consequently, the action
of MMPs and their inhibitors, TIMPs and RECK, are also important regulators of
development.
1.7.1. Cell migration and tissue remodeling in development
Cell migration is vital during embryonic development and permits the cellular
rearrangements and cell signaling processes that are required for many important
developmental events, the earliest of which are gastrulation and germ layer induction.
Migration is largely mediated by the activity of MMPs, which cleave ECM components,
releasing cytokines and clearing a space in the ECM through which cells can move. For
example, one process that is absolutely dependent on cell motility is the migration of the
neural crest cells away from the neural tube to form the sensory ganglia (Prendergast, Linbo
et al. 2012). Although MMPs are required during this process, MMP activity must also be
tightly regulated to prevent aberrant development. RECK has been implicated as an
important regulator of neural crest cell migration as studies examining early zebrafish
development showed that mutation in the RECK gene inhibited proper formation of the
dorsal root gangia (Prendergast, Linbo et al. 2012).
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Cell migration is also essential during long bone development, at which time
osteoclasts must invade the cartilage primordium in order to begin the process of
endochondral ossification. Osteoclast invasiveness has been shown to rely on high expression
and activity of MMP-9, where cell migration into the cartilage matrix is limited by MMP
inhibitors (Blavier and Delaisse 1995). MT1-MMP may also play an important role in
regulating bone development as MT1-MMP knockout mice display severe skeletal defects
including craniofacial abnormalities and dwarfism (Holmbeck, Bianco et al. 1999).
Additionally, the MT1-MMP null mouse has more acute developmental defects compared to
other MMP knockout mouse models, indicating the significance of this multifunctional
protein in regulating developmental events (Zhou, Apte et al. 2000).
Proper development of the central nervous system (CNS) is another process that is
highly reliant on cell migration and invasion. During CNS development, neurons must extend
long axonal extensions to form synaptic connections, and MMP-9 has been shown to be an
important regulator of neuronal outgrowth (Chambaut-Guerin, Herigault et al. 2000).
Aberrant regulation of MMP-9 during neural development can lead to CNS defects and
improper synapse formation; therefore, it is not surprising that TIMPs have been associated
with tight regulation of MMP activity during this time. TIMP-1 knockout mice exhibit
significant neuronal impairment, and have difficulty forming and retaining reward
associations compared with wild-type mice (Chaillan, Rivera et al. 2006). Similarly, TIMP-2
null mice exhibit neurological abnormalities and motor dysfunction, highlighting the
importance of maintaining the balance between MMP and TIMP activity during development
(Jaworski, Soloway et al. 2006).
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1.7.2. ECM-dependent regulation of angiogenesis
One of the most well studied developmental processes is angiogenesis, the formation
and branching of blood vessels that allows for complete vascularization of the animal. The
requirement for proper blood vessel formation during embryonic development, coupled with
the role of this process in facilitating tumor progression, has made angiogenesis a hot topic of
research in the last several decades. Angiogenesis is highly dependent on the action of MMPs
and their inhibitors, TIMPs and RECK. During angiogenesis, cells must first migrate into the
surrounding ECM. Branching morphogenesis follows, which is an organized process that is
very reliant on MMP activity. MMPs are needed to clear space in the ECM, which permits a
column of endothelial cells to advance forward and migrate into the extracellular space,
forming a new blood vessel and eventually leading to vascularization of the tissue (StetlerStevenson 1999). In addition to cell motility, the formation of tubular structures and branch
points during angiogenesis also requires changes in cell shape, proliferation, and the
formation of new cell contacts (Vu and Werb 2000). Following proliferation and migration
into the ECM, endothelial cells tightly adhere to one another and to the BM, and form a
lumen for the new blood vessel (Stetler-Stevenson 1999). This process is largely driven by
cell interactions with the ECM and requires tightly regulated ECM remodeling events.
In particular, MMP-2, MMP-9 and MT1-MMP have been associated with
angiogenesis. Although MMP activity is required for blood vessel development, the action of
TIMPs and RECK must be precisely regulated during this process as well (Handsley and
Edwards 2005). While the N-terminal domain of TIMP-2 directly inhibits MMPs, the TIMP2 C-terminal domain also has demonstrated anti-angiogenic activity in vivo. As previously
mentioned, the carboxy terminus of TIMP-2 can bind α3β1 integrins leading to reduced
proliferation of endothelial cells (Feldman, Stetler-Stevenson et al. 2004). Additionally,
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association of TIMP-2 with α3β1 integrins led to enhanced expression of RECK, which
subsequently decreased endothelial cell migration through inhibition of MMP-2, -9, and
MT1-MMP (Oh, Seo et al. 2004).
Just as excessive inhibition of MMP activity can have negative effects on
angiogenesis, too little inhibition of MMP activity is also associated with defects in
vascularization. RECK deficient embryos die at embryonic day 10.5 as a result of arrested
vascular development (Oh, Takahashi et al. 2001). Histological examination of these
embryos showed that the blood vessels were abnormally large and deformed, demonstrating
the requirement for MMP inhibitors in mediating MMP activity during angiogenesis
(Chandana, Maeda et al. 2010). Thus, these studies again emphasize the requirement for
balance between MMP, TIMP and RECK activity in the ECM.

1.7.3. ECM-dependent regulation of cell signaling in development
In addition to the direct roles of MMPs and their inhibitors in regulating ECM
remodeling during development, the activities of MMPs, TIMPs and RECK can also
contribute to important ECM associated signaling events, which may help to pattern
development. MMP-mediated release of growth factors from the ECM may be important in
initiating developmental processes. MMP-1 and MMP-3 are known to release bound FGF
from the ECM, whereas MMP-2, -3 and -7 are involved in the release of TGF-β (Whitelock,
Murdoch et al. 1996; Imai, Hiramatsu et al. 1997). As FGF plays important roles in
chondrocyte differentiation and proliferation, its release from the ECM may contribute to
cartilage development. Similarly, TGF-β signaling is involved in branching morphogenesis;
therefore, MMPs may indirectly play a role in regulating these processes through release of
growth factors from the ECM (Vu and Werb 2000).
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Given the multiple roles of the TIMP C-terminal domains in regulating cell motility,
proliferation, and apoptosis pathways in vitro, it is evident that TIMPs may also have
important functions in development aside from their direct roles in mediating ECM turnover.
Although there is limited research that has investigated the precise roles of TIMPs in
mediating cell signaling in vivo, we can infer the significance of these molecules in
regulating developmental signaling events based on the numerous in vitro studies that have
been performed. Currently, a large amount of our knowledge regarding MMP/TIMP function
in vivo is based on correlation with their expression patterns in development, as well as their
known activities during pathogenesis (Vu and Werb 2000). In particular, further research is
needed to investigate TIMP domain function in vivo. Our understanding of these proteins as
MMP inhibitors has been confounded by the more variable roles of their C-terminal domains
in cell signaling, which currently have only been examined in vitro. As MMPs and TIMPs
are both expressed and tightly regulated during development, when ECM remodeling is high,
a good in vivo approach is to use a developmental model system to examine MMP/TIMP
function.

1.8 Animal Model
The organism used as an animal model in this research is Xenopus laevis, commonly
known as the African clawed frog. Xenopus laevis has been an important model organism in
the field of developmental biology since the 1950’s and remains a prominent model organism
in the developmental field due to its numerous advantages. A single X. laevis female can
produce hundreds of eggs in a controlled manner by injecting the hormone gonadotropin.
Xenopus laevis eggs are fertilized externally and embryos are easily maintained and reared in
simple salt solution at room temperature. Developmental processes are easily observed in X.
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laevis embryos due to the large size of the embryos and their blastomeres. Development
occurs rapidly and has been thoroughly studied in X. laevis embryos. Cell movements and
detailed fate maps have also been well characterized. Xenopus laevis embryos have easily
recognizable developmental stages, which are well described. Gastrulation occurs at stage
10; neurulation begins at stage 14 and continues through to stage 20 (during which time
neural crest cell migration is beginning), ending with closure of the neural tube; and
organogenesis occurs from stage 28 to stage 40 (during which time angiogensis is
beginning). Each stage has recognizable structures and is associated with specific signaling
pathways that can be utilized to examine developmental events, such as ECM proteolysis.
For instance, it has previously been shown that disrupting the ECM during X. laevis
development has detrimentral effects. Ectopic expression of MT3-MMP and TIMP-3 have
been demonstrated to lead to embryonic lethality through unknown mechanisms (Pickard and
Damjanovski 2004; Walsh, Cooper et al. 2007). Thus, this model organism can be used to
further examine the importance of these ECM remodeling events, and to investigate more
precisely how disruption of proper ECM remodeling may affect development.
In addition, X. laevis embryos are robust, largely resilient to experimental
manipulation, and may be grafted or injected. Embryos are able to withstand extensive
surgical micromanipulation in vitro and heal readily. One drawback of using X. laevis
experimentally is that embryos are not ideally suited for transgenic manipulation due to their
pseudotetraploid genome and long generation time to reach sexual maturity (2 years).
However, X. laevis embryos are extremely resistant to microinjection, and are able to
translate synthetic mRNA. This technique can be used for overexpression studies, and can be
extrememly useful in understanding developmental signaling events.
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A great deal of our current knowledge regarding early embryonic development comes
from studies performed using X. laevis embryos. Xenopus laevis remains an important model
organism in the study of developmental biology. For these reasons I chose to use X. laevis as
my model organism for studying ECM remodeling events and cell signaling events
associated with TIMP N- and C-terminal domains.
1.9 Research Questions
1.9.1. Summary
Remodeling of the ECM is required for the development and maintenance of
multicellular organisms. Extracellular matrix remodeling occurs primarily through the action
of MMPs, which cleave ECM components, and their endogenous inhibitors, TIMPs and
RECK. The delicate balance between TIMPs, RECK, and MMPs are required to mediate
developmental processes where large-scale tissue remodeling occurs, including angiogenesis,
neural development, bone formation, and organogenesis. Disruption in the expression or
activities of these molecules within the ECM proteolytic network can lead to developmental
abnormalities and death.
TIMPs are multifunctional proteins that have additional functions aside from MMP
inhibition. TIMPs are involved in regulating a number of cell signaling pathways, including
cell growth, migration, and apoptosis, and this activity is mediated through the C-terminus of
TIMP proteins, independent of their MMP-inhibitory activity (which occurs exclusively at
the N-terminus). There is little information regarding TIMP domain function in vivo,
however, the relative levels of MMPs and TIMPs plays a role in regulating the availability of
TIMPs at the cell surface, and subsequently, their ability to participate in signaling events. To
date, much of the work characterizing TIMP signaling activity has been carried out in vitro,
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and TIMP roles in cell signaling seem to vary with the cell line examined. Accordingly, there
is a need to examine TIMP function (particularly in cell signaling) in vivo. My research
characterizes TIMP function in vivo, using X. laevis as a model to examine the role of the
TIMP domains during development. Specifically, this research investigates the balance
between TIMP MMP-inhibitory functions and TIMP roles in cell signaling during
development, and is the first comprehensive comparison of the roles of the TIMP N- and Cterminal domains in vivo.

1.9.2. Hypotheses
1) The N-terminal domain sequences of each TIMP will be more highly conserved than
the C-terminal domains, as TIMP MMP-inhibitory activity is the common function
of these proteins.
2) Overexpression of TIMP N-terminal domains will all produce similar developmental
defects resulting from increased inhibition of MMP activity, due to the fact that
TIMPs are largely redundant in their MMP-inhibitory abilities.
3) Overexpression of TIMP-1 and -2 C-terminal domains will produce unique
developmental defects, resulting from specific changes in cell signaling pathways;
whereas, the TIMP-3 C-terminal domain will have limited influence on
development, as there is currently little research supporting a direct role for the
TIMP-3 C-terminal domain in cell signaling.
4) Overexpression of TIMP N-terminal domains will result in similar alterations in
expression and activity of proteolytic molecules; whereas, overexpression of the C-
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terminal domains will have varying effects on developmental regulation of these
molecules that is dependent (presumably) on their roles in cell signaling.

1.9.3. Objectives
The goal of this research was to compare the unique functions of the N- and Cterminal domains with those of the full-length molecule for all three known X. laevis TIMPs
during development. TIMP-2 and -3 had previously been cloned when I began this research.
Through database searches and analysis I have cloned TIMP-1, however, there does not
appear to be a TIMP-4 (discussed in Chapter 5) in X. laevis. This research had the following
objectives:
1) Identify and characterize Xenopus laevis TIMP-1 (Chapter 3).
2) Perform a comparison of amino acid sequence identity for the N- and C-terminal
domains of each TIMP to determine their evolutionary conservation (Chapter 2 and
3).
3) Use X. laevis TIMP-1, -2 and -3 sequences to generate TIMP-1, -2 and -3 full-length,
N-terminal, and C-terminal domain mRNA constructs (Chapter 2 and 3).
4) Overexpress each TIMP construct in X. laevis embryos using mRNA microinjection.
Examine embryos for resultant morphological changes and developmental
abnormalities, to determine how each TIMP domain may contribute to large-scale
patterning of embryonic development (Chapter 2 and 3).
5) Examine alterations in mRNA levels of proteolytic genes, as well as changes in MMP
activity, following overexpression of each TIMP construct to elucidate how the

36
individual TIMP domains may contribute to the regulation of the ECM proteolytic
network (Chapter 2 and 3).
6) Examine embryos injected with each TIMP construct to investigate changes in levels
of key indicators of cell signaling pathways associated with overexpression of each
TIMP domain (Chapter 4).
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CHAPTER 2
DOMAIN SPECIFIC OVEREXPRESSION OF TIMP-2 AND TIMP-3 REVEALS MMPINDEPENDENT FUNCTIONS OF TIMPS DURING XENOPUS LAEVIS DEVELOPMENT

This work has previously been published as “Nieuwesteeg, M. A., Walsh L.A., Fox, M.A.,
and Damjanovski, S. (2012). Domain specific overexpression of TIMP-2 and TIMP-3 reveals
MMP-independent functions of TIMPs during Xenopus laevis development. Biochem Cell
Biol 90(4): 585-595”. NRC research press Copyright Clearance Center permits reuse of
figures, tables and excerpts from any NRC Research Press article, for any purpose that
respects the moral rights of authors without permission. The text has been modified form the
original manuscript to adhere to formatting guidelines for this thesis. Experiments were
designed and carried out by M.A.N., L.A.W. assisted with embryo rearing, M.A.F. assisted
with Western blotting, S.D. provided funding, resources, and intellectual contributions.
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2.1 Introduction
2.1.1. TIMP overview
ECM remodelling carried out by MMPs and TIMPs is important in regulating
development in multicellular organisms, and mediates processes involving large-scale cell
movements and rearrangements, including gastrulation, organogenesis and angiogenesis
(Blavier and DeClerck 1997; Gomez, Alonso et al. 1997; Damjanovski, Amano et al. 2001;
Zhang, Bai et al. 2003; Nuttall, Sampieri et al. 2004; Myers, Applegate et al. 2011). As
discussed in Chapter 1, although TIMPs were originally characterized as endogenous MMP
inhibitors, it is now known that TIMPs contain structurally and functionally distinct N- and
C-terminal domains, and that the TIMP C-terminal domains may be involved in direct
regulation of a number of signaling pathways (Murphy, Unsworth et al. 1993; Guedez,
Stetler-Stevenson et al. 1998; Ahonen, Poukkula et al. 2003; Chirco, Liu et al. 2006;
Vanhoutte and Heymans 2010; Kallio, Hopkins-Donaldson et al. 2011). The two TIMP
domains are thought to have evolved separately, and both domains have the ability to fold
and function independently (Brew and Nagase 2010). This has been demonstrated through
expression of TIMP N-terminal domains in heterologous systems, where the N-terminal
TIMP domains still maintain a stable native structure, and can inhibit MMPs (Bahudhanapati,
Zhang et al. 2011).
The four mammalian TIMPs all have a similar structure and are highly conserved at
the amino acid level (Bode, Fernandez-Catalan et al. 1999; Murate and Hayakawa 1999). The
highest degree of sequence similarity occurs within TIMP N-terminal domains, whereas the
C-terminal domains are more variable (Pavloff, Staskus et al. 1992; Apte, Hayashi et al.
1994; Bodden, Harber et al. 1994; Leco, Khokha et al. 1994; Fernandez, Butterfield et al.
2003; Brew and Nagase 2010). As discussed in section 1.5.3., TIMP-2 is the most well
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characterized, and in human endothelial cells has been demonstrated to bind α3β1 integrins
through its C-terminus, leading to an upregulation in RECK, which subsequently
downregulates MMP activity and decreases cell migration (Oh, Seo et al. 2004; Shakibaei,
Csaki et al. 2008). While the C-terminal domains can act MMP-independently, the Nterminal domains of all TIMPs are involved in direct binding and inhibition of the bound
MMP's catalytic activity.

2.1.2. TIMPs and MMPs in development
To date, most research characterizing TIMP domain function has been carried out in
vitro, where the activation of a given cell signaling pathway is dependent on both the specific
TIMP expressed, and the cell type it is expressed in (Stetler-Stevenson 2008; Bourboulia and
Stetler-Stevenson 2010). Although maintaining the correct MMP/TIMP balance is essential
for proper development, little is known regarding the relationship between TIMPs and MMPs
during embryogenesis. TIMP-1, -2 and -3 knockout mice are viable (reviewed in Brew and
Nagase 2010), suggesting overlapping redundancies in their functions. In contrast, while
many MMP knockouts have been generated, only the MMP-14 (MT1-MMP) null mouse
shows severe consequences (Zhou, Apte et al. 2000). MMP overexpression during X. laevis
development results in both axial defects and death shortly after gastrulation, although
specific mechanisms are not known (Hasebe, Hartman et al. 2007; Walsh, Cooper et al.
2007). Additionally, TIMP-3 overexpression is lethal to X. laevis during development;
however, it is unclear whether this occurs as a result of aberrantly activated cell signaling
pathways, or as a result of improper ECM remodelling (Pickard and Damjanovski 2004).
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2.1.3. Summary and research questions
At the time this research was published, only TIMP-2 and -3 had been cloned in X.
laevis (Yang and Kurkinen 1998; Klein, Strausberg et al. 2002). Mammalian TIMP-2 has
been well characterized in vitro and is known to be localized pericellularly and associated
with a number of cell signaling pathways (Stetler-Stevenson 2008). In contrast, TIMP-3
interacts with sulphated GAGs and is sequestered in the ECM, away from the cell surface
(Silbiger, Jacobsen et al. 1994; Yu, Yu et al. 2000). To elucidate the roles of TIMPs and their
domains during development, I used mRNA microinjection to disrupt endogenous TIMP
levels and overexpressed TIMP-2 and -3, or their individual N- or C-terminal domains in X.
laevis embryos. Ectopic expression of TIMP-2 and -3 as well as their N- and C-terminal
domains led to distinct developmental disruptions, suggesting MMP-dependent and
independent functions. Additionally, zymography and PCR analysis showed that the TIMP
N- and C-terminal domains led to differential changes in MMP activity, and the expression
of marker genes, indicating that each domain has unique downstream effects.

2.2 Materials and Methods
2.2.1. Sequence analysis of vertebrate and invertebrate TIMP-2 and -3 N- and C-terminal
domains
Sequence alignments and amino acid sequence identity were performed using
ClustalW2

analysis

software

at

the

European

Bioinformatics

Institute

site

at

http://www.ebi.ac.uk/Tools/clustalw2/index.html. Phylogenetic comparisons were performed
using Molecular Evolutionary Genetic Analysis (MEGA) 5.2.1. software to construct a
neighbour-joining tree with a bootstrap of 1000.
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2.2.2. Animals
Adult X. laevis were purchased from Xenopus I Inc (Dexter, MI). Embryos were
fertilized and reared in accordance with standard protocols (Sive H.L. 2000) and staged
according to Nieuwkoop and Faber (Nieuwkoop P.D. 1956). Animals were housed and
treated according to UWO and CCAC guidelines.

2.2.3. Cloning of X. laevis TIMP-2 and -3
X. laevis TIMP-2 and TIMP-3 sequences were previously identified (AF042493 and
MGC84288, respectively). I cloned X. laevis TIMP-2 and -3 from total adult liver cDNA
using SuperScriptTM Reverse Transcriptase (Invitrogen) with Platinum® Taq DNA
Polymerase High Fidelity (Invitrogen). The coding regions of both TIMP-2 and -3 were
cloned using specific primers based on the above sequences. The full-length TIMP-2 and -3
amplicons were cloned into the pCR®II-TOPO vector (Invitrogen), and sequences were
confirmed at the Robarts Research Institute DNA Sequencing Facility at the University of
Western Ontario.

2.2.4. Generation of TIMP-2 and -3 mRNA constructs for microinjection
PCR was used to generate full-length, N-terminal or C-terminal TIMP-2 and -3
(hemagglutinin) HA-tagged constructs using the full-length clones as templates. Briefly, all
TIMP constructs (T2FL, T2N, T2C, T3FL, T3N, T3C) were HA-tagged on their C-terminal
ends. In addition, the two C-terminal domain constructs (T2C and T3C) were engineered to
include their appropriate secretory signal sequence through a two-step PCR process.
Following PCR amplification, the sequences of all amplicons were verified. All TIMP-2 and
-3 constructs were subsequently ligated into the BglII/SpeI restriction sites of the T7TS

!

47

plasmid. mMessage mMachine (Ambion) was used with T7 RNA polymerase (Ambion) to
synthesize stable capped, poly(A)-tailed mRNA transcripts that were dissolved in filtered
water. mRNA was quantified using Nanovue spectrophotometer (GE), and its integrity was
assessed using 1% agarose gel electrophoresis. Green fluorescent protein (GFP) mRNA was
generated and quantified in a similar way from a proven T7TS construct plasmid (Walsh,
Cooper et al. 2007).

2.2.5. mRNA microinjection
Prior to injection, fertilized X. laevis embryos at the 1 cell stage were transferred from
0.1X Marc’s modified ringers (MMR) into 1X MMR containing 4% Ficoll. Embryos were
injected at the 1 cell stage with TIMP-2 or -3 full-length, N-terminal, or C-terminal
constructs using 10 µm diameter glass needles. Embryos were injected with 4 ng of mRNA
construct in a volume of 2.3 nl. Embryos were maintained in 1X MMR with Ficoll for 5 hr
following injection, then transferred to 0.1X MMR solution for rearing. Embryos that were
dead or abnormal 2 hr post-injection were removed, and the remaining embryos (representing
the 100% being monitored) were examined for phenotypic abnormalities. The percent of
normal embryos present (no clear visible defects) were quantified for two days following
injection. Mean values were obtained from 3 independent sets of experiments.

2.2.6. Protein preparations and Western blotting
Stage 30 embryos injected with the various mRNA constructs, or uninjected controls,
were subject to protein extraction. Briefly, 10 embryos were lysed and sonicated in 100 µl
lysis buffer (150 mM NaCl, 50 mM Tris-HCl (pH 7.5), 1% Triton X-100, 0.1% SDS, 1%
deoxycholate, 50 mM sodium flouride, 1 mM sodium orthovanadate, 0.1% NP-40 protease
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inhibitor cocktail (Roche Applied Science, Indianapolis, IN)). Lysates were centrifuged at
15,000 g for 15 min at 4°C, the supernatant was removed, and protein was quantified using
BCA protein assay kit (Thermo Scientific) in accordance with the manufacturer’s
instructions. Equal amounts of protein (25 µg) were electrophoresed on a 10% SDS gel and
transferred to PVDF membrane (Bio-Rad). Membranes were washed three times with TBST
(Tris-buffered saline containing 0.5% Tween 20), blocked using 5% skim milk in TBST for
30 min at room temperature, and incubated overnight at 4°C with primary antibody. Primary
antibodies used were rabbit anti-HA, 1/1000 dilution (Invitrogen) or mouse anti-β-actin,
1/1000 dilution (Invitrogen). After washing 3 times in TBST, membranes were incubated
with secondary antibody (goat anti-rabbit HRP, 1/5000 dilution; Invitrogen, or goat antimouse HRP, 1/5000 dilution; Invitrogen) for 1 hr at room temperature. Membranes were
washed 3 times in TBST and peroxidase activity was detected using SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientific), and visualized, standardized to actin levels,
and photographed using Bio-Rad Quantity One 4.4.0 software.

2.2.7. Zymography
Briefly, 12.5 µg of protein from injected embryos (as described above) was diluted
1:1 with 2X SDS-loading buffer (0.5 M Tris-HCl (pH 6.8), 10% SDS, 2.5 % glycerol, 1%
bromophenol Blue), and then analyzed by gelatin zymography. Protein samples were loaded
into a 10% gelatin zymogram gel (Bio-Rad), and electrophoresed in 1X zymogram running
buffer (25 mM Tris, 192 mM glycine, 0.1% SDS), followed by in-gel renaturation for 30 min
at room temperature in renaturing solution (2.5% Triton X-100). Substrate cleavage was
carried out by incubating gels in zymogram developing buffer (pH 7.5, 50 mM Tris, 200 mM
NaCl, 5 mM CaCl2 (anhydrous), 0.02% Brij-35) for 48 hr at 37°C. The gelatinolytic activity
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was visualized as a clear band in the blue background after staining with 0.5% Coomassie
blue. Gels were visualized and photographed, and densitometry was performed using BioRad Quantity One 4.4.0 software.

2.2.8. Real-Time PCR of marker genes
To investigate changes in the expression of embryonic genes following injection of
the various TIMP constructs, real-time qPCR was performed using the CFX96™ Real-Time
PCR Detection System (Bio-Rad) in a two-step procedure using PerfeCTa® SYBR® Green
SuperMix (Quanta Biosciences). Amplification of the Ef-1α gene was performed to
standardize the amount of sample cDNA. Primers, based on the X. laevis sequences, were as
follows: Ef-1α 5’CTACAAATGTGGTGGCATCG and 5’GCTCTGCCTTCAGTTTGTCC;
RECK 5’AGTGAAGGATGCACCAAACC and 5’GCAGTTCAGCACCATCAAGA; β1
integrin 5’CTGACGCAGGATTCCATTTT and 5’GTGTACATGTTCCCGTGCAG; MMP2 5’AGGAGAAGGCCAAGTTGTGA and 5’CTGAGCGACCAGAATCAGTG; MMP-9
5’CTGGGACTGAAGGAGACTGG and 5’CCCCCTCAAATGTGTTGAAT. All reactions
were performed in a 96 well plate using the following cycling conditions: 40 cycles of 95 °C
for 15 sec, 60 °C for 30 sec, and 72°C for 1 min. Using the ΔΔCT (delta-delta CT) method,
the value of each control sample was set at 1 and used to calculate the fold change of target
genes.

2.3 Results and Discussion
Understanding of TIMP function has been confounded by the realization that TIMPs
may also bind to a variety of cell surface receptors through their C-terminal domains and
mediate a number of cell signaling pathways in an MMP-independent manner (Lambert,
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Dasse et al. 2004). There is currently little information regarding how TIMP proteins
function in vivo, particularly as their domains may act through both MMP-dependent and
independent mechanisms (Stetler-Stevenson 2008). In this study I examined the individual
domains of TIMP-2 and -3 in early stage X. laevis embryos in order to gain an understanding
of how the individual N- and C-terminal domains may regulate key developmental events, as
there is evidence that TIMP N- and C-terminal domains may have unique properties, function
independently as individual domains, and maintain their native topology (Bahudhanapati,
Zhang et al. ; Chirco, Liu et al. 2006; Brew and Nagase 2010; Bahudhanapati, Zhang et al.
2011; Wu, Wei et al. 2011).

2.3.1. The N- and C-terminal domains of X. laevis TIMP-2 differ in their sequence
conservation
A direct comparison of amino acid sequence identities of the individual X. laevis
TIMP-2 N- and C-terminal domains with other vertebrate and invertebrate species is of
particular interest, as I investigated in vivo whether TIMP N- and C-terminal domains could
function independently of one another, and how these roles may be reflected in their
evolutionary conservation. My analysis indicated that for TIMP-2, the N-terminal MMPinhibitory domains were more highly conserved across most vertebrate species analyzed,
including both mammals and non-mammals, than the C-terminal domains (Fig. 2.1 A), a
finding that has been previously reported (Brew and Nagase 2010). This may reflect the fact
that the N-terminal domain has only one primary role, to bind to and inhibit MMP activity.
As the catalytic domains of MMPs are conserved across species (Van Wart and BirkedalHansen 1990), this TIMP domain is also conserved. Interestingly, Caenorhabditis elegans
TIMP-2 does not contain the region corresponding to the vertebrate C-terminal domain,
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suggesting the possibility that the TIMP-2 C-terminal domain signaling mechanism evolved
only in higher vertebrates. In contrast, the TIMP-2 C-terminal domains were slightly more
variable (Fig. 2.1 A), suggesting that their role, presumably in cell signaling, may vary
between species. The C-terminal domain may have evolved concomitant with changes in
receptor and cell signaling pathways. However, phylogenetic analysis comparing the X.
laevis TIMP-2 N- or C-terminal domains with other species showed that both the N- and Cterminal domains had a similar branching patterns in their phylogenetic trees, but diverged at
different rates (Fig. 2.1 B vs. C).

!

52

Figure 2.1. Evolutionary conservation of TIMP-2 N- and C-terminal domains. (A)
Sequence analysis comparing amino acid sequence identity of X. laevis TIMP-2 N- and Cterminal domains among several vertebrates and invertebrates. Light grey boxes represent
species whose N-terminal domains were more highly conserved with X. laevis TIMP-2 than
their C-terminal domains. Dark grey boxes represent species whose C-terminal domains were
more highly conserved with X. laevis TIMP-2 than their N-terminal domains. (B)
Phylogenetic tree showing sequence divergence among TIMP-2 N-terminal domains as
generated by MEGA 5.2.1. software. (C) Phylogenetic tree showing sequence divergence
among TIMP-2 C-terminal domains as generated by MEGA 5.2.1. software. The C. elegans
sequence was removed from phylogenetic analysis as the C-terminal domain was missing.
Accession numbers are as follows: Xenopus (Xenopus laevis) AF042493, Human (Homo
sapiens) AAB19474.1, Mouse (Mus musculus) AAA40446.1, Chicken (Gallus gallus)
NP_989629.1,

Zebrafish

(Danio

rerio)

NP_878294.1,

BAE06264.1, Elegans (Caenorhabditis elegans) AAA96174.

Fugu

(Takifugu

rubripes)
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2.3.2. The C-terminal domain of X. laevis TIMP-3 is conserved
In contrast to TIMP-2, when I examined the individual domains of TIMP-3 I found
the opposite trend; the TIMP-3 C-terminal domains were more conserved with X. laevis
TIMP-3 than their N-terminal domains across all vertebrate species examined (Fig. 2.2 A).
However, this relationship was not true for invertebrates, as the N-terminal domain of sea
urchin TIMP-3 was more conserved. TIMP-3 is unique in that it is the only TIMP that binds
directly to the ECM, and studies have shown that the C-terminal domain of TIMP-3 is
important for facilitating this binding (Yu, Yu et al. 2000). Langton et al. (1998) expressed
both full-length and truncated forms of TIMP-3 in Cos-7 cells, and demonstrated that fulllength and C-terminal TIMP-3 were able to bind to the ECM, whereas N-terminal TIMP-3
could not (Langton, Barker et al. 1998). Therefore, the C-terminal domain of TIMP-3 may
have a conserved role in mediating its attachment to the ECM, at least among vertebrate
species, while its N-terminal domain functions to inhibit MMP activity. Phylogenetic
analysis comparing X. laevis TIMP-3 N- and C-terminal domains with other species showed
that, unlike TIMP-2, the two domains followed a slightly different evolutionary trend,
suggesting that the individual domains in TIMP-3 evolved under different selective pressures
(Fig. 2.2 B and C).
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Figure 2.2. Evolutionary conservation of TIMP-3 N- and C-terminal domains. (A)
Sequence analysis comparing amino acid sequence identity of X. laevis TIMP-3 N- and Cterminal domains among several vertebrates and invertebrates. Light grey boxes represent
species whose N-terminal domains were more highly conserved with X. laevis TIMP-3 than
their C-terminal domains. Dark grey boxes represent species whose C-terminal domains were
more highly conserved with X. laevis TIMP-3 than their N-terminal domains. (B)
Phylogenetic tree showing sequence divergence among TIMP-3 N-terminal domains as
generated by MEGA 5.2.1 software. (C) Phylogenetic tree showing sequence divergence
among TIMP-3 C-terminal domains as generated by MEGA 5.2.1 software. Accession
numbers are as follows: Xenopus (Xenopus laevis) MGC84288, Human (Homo sapiens)
AAB60373.1, Mouse (Mus musculus) AAA40447.1, Cow (Bos taurus) NP_776898.2, Fugu
(Takifugu rubripes) BAE06261.1, Salmon (salmo salar) ACN10551.1, Sea Urchin
(Strongylocentrotus purpuratus) XP_781027.1.
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2.3.3. Overexpression of full-length TIMP-2 and -3 resulted in different developmental
phenotypes
To assess the roles of TIMP-2 and -3 during X. laevis development, I generated and
overexpressed full-length TIMP-2 or -3 mRNA constructs in newly fertilized X. laevis
embryos. Embryos were injected at the 1 cell stage and analyzed for gross morphological
changes in development until stage 30 (approximately 2 days following injection). Real-time
PCR analysis was used to confirm upregulation of TIMP-2 or -3 mRNA levels following
injection of each construct. This verified that injected embryos all contained relatively equal,
but elevated levels of TIMP mRNA compared with uninjected embryos. Additionally, to
compare relative protein levels following injection, Western blotting against HA-tags was
used. This confirmed that all proteins produced were present in equal amounts (Fig. 2.3). The
percentage of normal embryos (embryos that were alive and morphologically normal) was
determined and quantified at stage 15 (one day post-injection) and stage 30 (two days postinjection). Over 90% of control uninjected embryos and embryos injected with GFP mRNA
developed normally during this 48 hr period (Fig. 2.4 A and B). In comparison, injection of
embryos with full-length TIMP-2 or -3 (T2FL and T3FL, respectively) mRNA resulted in
serious developmental defects, with T3FL being more detrimental than T2FL (Fig. 2.4 A and
B). By stage 30, 55% of T2FL injected embryos developed normally, whereas only
approximately 10% of T3FL injected embryos developed normally (Fig. 2.4 A and B).
Phenotypically, T2FL injected embryos displayed axial defects (truncated, curved axes), and
neural tube closure failure (Fig. 2.5 A). In contrast, while overexpression of T3FL also
resulted in axis defects (truncated, curved axes), these embryos did not display neural tube
closure defects.
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Figure 2.3. Microinjection of 4 ng of TIMP-2 or -3 mRNA constructs produces equal
amounts of HA-tagged protein in X. laevis embryos. Following the injection of equal
amounts of mRNA (4 ng) at the 1 cell stage, protein was isolated from stage 30 embryos.
Equal amounts of protein were electrophoresed on a 10% SDS gel. TIMP constructs were
detected using an anti-HA antibody. Images are of representative bands after normalization
to β-actin levels. The left panel shows bands corresponding to TIMP-2 full-length (T2FL), Nterminal (T2N), and C-terminal (T2C) constructs. TIMP-3 full-length (T3FL), N-terminal
(T3N), and C-terminal (T3C) constructs are shown in the right panel.

!

59

2.3.4. Overexpression of TIMP-2 N- or C-terminal domain constructs resulted in more
developmental defects than overexpression of full-length TIMP-2
Overexpression of the individual N- or C-terminal domains of TIMP-2 resulted in
distinctive survival rates as well as developmental defects. Following injection of either
domain of TIMP-2 (T2N and T2C constructs), embryos displayed morphological defects
similar to T2FL injected embryos (truncated, curved axes, and neural tube closure failure;
Fig. 2.5 A); however, the effects were more severe as less than 30% of T2N and T2C injected
embryos developed normally, compared to 55% normal development with the T2FL
construct (Fig. 2.4 A). The two domains also manifested their effects at different rates, as by
stage 15 only 30% of T2N injected embryos developed normally, versus 50% normal at this
time point with the T2C construct. Thus, the T2N construct was more detrimental at this time
point (Fig. 2.4 A). By stage 30, T2N and T2C injected embryos displayed similar scores with
only 21% and 26% normal development, respectively, both of which were more detrimental
than the T2FL injections (Fig. 2.4 A). Overexpression of T2FL, T2N, and T2C constructs all
produced large-scale morphological defects including head defects, curved, truncated axes,
and failure of the neural tube to close (Fig. 2.5 A; see appendix C for additional images).
Since overexpression of all three constructs disrupted the proper formation of the neural tube,
this suggests that a combination of both TIMP-2 cell signaling (via the C-terminal end) and
MMP-inhibitory activity (via the N-terminal end) may be required for normal development
of the neural tube.
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2.3.5. Overexpression of full-length TIMP-3 or its N-terminal domain construct resulted in
more developmental defects than overexpression of the TIMP-3 C-terminal domain
construct
The consequences of injecting full-length TIMP-3 and its N- or C-terminal domain
did not follow the same pattern as TIMP-2. T3FL injections caused a variety of defects that
resulted in only 15% normal embryos by stage 30 (Fig. 2.4 B). A similar rate of defects was
also displayed in T3N injected embryos (Fig. 2.4 B), and both T3FL and T3N injected
embryos also had truncated, curved axes and head and eye malformation (Fig. 2.5 B). These
defects and phenotypes were in contrast to the T3C injected embryos, which had over 70%
normal development at stage 30 (Fig. 2.4 B). Indeed, most surviving T3C embryos displayed
little to no morphological defects (Fig. 2.5 B; see Appendix C for additional images). Thus, I
observed that T3FL and T3N constructs were approximately 5-fold more toxic to X. laevis
embryos than T3C (15% vs 70% normal at stage 30; Fig. 2.4 B). In contrast, the T2N and
T2C constructs were more than twice as toxic as T2FL (Fig. 2.4 A). The observation that
T3FL and T3N overexpression resulted in developmental defects including curved, truncated
axes, as well as anterior malformations, was consistent with in situ hybridization studies that
showed TIMP-3 expression in the head and eye (Pickard and Damjanovski 2004).
Additionally, T3FL and T3N constructs resulted in high levels of lethality compared with
T3C (Fig. 2.4 B), and T3C overexpression resulted in embryos that did not display any
serious development defects (Fig. 2.5 B). This indicates that it is the N-terminal domain of
TIMP-3 that is involved in mediating developmental events, and this likely occurs through
direct inhibition of MMP activity. The C-terminal domain of TIMP-3 on its own appears to
play no major role in development at this time.
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Figure 2.4. Overexpression of TIMP-2 and -3 led to abnormal development. Following
the injection of mRNA constructs at the 1 cell stage, embryos were scored for a normal
phenotype at stage 15 and stage 30 in development. The percent of normal embryos
following the injection of each construct was monitored and graphed. (A) Injections
consisted of 4 ng of mRNA encoding either TIMP-2 full-length (T2FL, red circle), Nterminal domain (T2N, purple triangle), or C-terminal domain (T2C, blue square) constructs,
or GFP (green circle). X represents uninjected controls. (B) Injections consisted of 4 ng of
mRNA encoding TIMP-3 full-length (T3FL, red circle), N-terminal domain (T3N, purple
triangle), or C-terminal domain (T3C, blue square) constructs, or GFP (green circle). X
represents uninjected controls. Results are based on the average of 3 independent sets of
experiments, where a minimum of 100 embryos were injected and counted for each replicate.
Bars indicate standard error (SE).
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Fig. 2.5 Overexpression of TIMP-2 and -3 resulted in specific morphological defects.
Four nanograms of mRNA encoding either GFP, or full-length, N-terminal or C-terminal
domain TIMP-2 or -3 were injected into X. laevis embryos at the 1 cell stage. Following
injection, photographs were taken of representative embryos at stage 30. Anterior is to the
left. GFP injected embryos were phenotypically normal. (A) Overexpression of TIMP-2 fulllength (T2FL), N-terminal (T2N) or C-terminal (T2C) constructs all caused similar early
developmental defects, and neural tube closure failure. (B) TIMP-3 full-length (T3FL) and
N-terminal (T3N) constructs resulted in axial defects and curvature. The C-terminal domain
TIMP-3 (T3C) construct did not produce severe malformations. Images are of representative
embryos where results were consistent between 3 independent sets of experiments, with a
minimum of 100 embryos injected per construct for each experiment. See appendix C for
additional images.
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2.3.6. Overexpression of TIMP constructs resulted in differential changes in MMP-2 and
-9 activity
Gelatin zymography was used to determine whether overexpression of TIMP-2 or -3,
or their individual domains altered the levels of active MMPs in developing embryos. I
looked specifically at the activities of MMP-2 and -9, as these are two potent ECM
remodelling proteins that have been shown to play important roles during development
(Carinato, Walter et al. 2000; Zhang, Bai et al. 2003). Interestingly, overexpression of all
TIMP constructs resulted in increased levels of active MMP-9, which was relatively low in
control embryos, whereas TIMP-mediated changes in active MMP-2 (which was
comparatively higher in control embryos) were much more subtle (Fig. 2.6). While it is
counterintuitive that none of the TIMP constructs resulted in decreased MMP-9 activity
relative to control embryos, (particularly the N-terminal constructs), the process of gelatin
zymography separates TIMP-MMP complexes, and as such, is a measure of the amount of
active MMP present in the embryo, as opposed to a direct measure of in vivo TIMP inhibition
of MMP activity (Toth and Fridman 2001). The observed increases in MMP-9 seen here
could have resulted from compensation in the embryos, whereby increasing the amount of
active MMP was a response to the attenuation of nascent MMP activity due to the injected
TIMP construct. Accordingly, the highest levels of active MMP-9 were observed in embryos
injected with T2N and T3FL constructs (Fig. 2.6), both of which would function mainly in
MMP inhibition. Additionally, this supports my embryo viability data, as these constructs
resulted in the most severe developmental phenotypes, with only 21% and 15% normal
development, respectively. With TIMP-3, the T3N construct also resulted in increased levels
of active MMP-9, however, not to the same extent as observed in the T3FL injected embryos
(Fig. 2.6). This was unexpected as both constructs should be involved predominantly in
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MMP inhibition, and the embryo viability data for both constructs was remarkably similar,
resulting in only approximately 15% survival by stage 30. This further highlights the distinct
functions seen between the N-terminal domains of TIMP-2 and -3, as reflected by their
distinct sequence conservation patterns between species.
The T3C construct caused very minor changes in MMP activity relative to control
embryos (Fig. 2.6), which corroborated my embryo viability data as injection with this
construct also resulted in very minor phenotypic abnormalities and 70% normal development
(Fig. 2.5 B). This provided further support that the TIMP-3 C-terminal domain plays no
independent role in early X. laevis development. Interestingly, the T2C construct did result in
increased levels of MMP-9 relative to control embryos. This increase, however, was not as
dramatic as that observed in T2N or even T2FL injected embryos (Fig. 2.6), even though
injection with the T2C construct was comparable with the T2N construct in terms of lethality
in the embryos (Fig. 2.5 A). This supports the idea that the C-terminal domain of TIMP-2
may work through a different mechanism to regulate MMPs during development.
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Figure 2.6. Overexpression of TIMP-2 or -3 and their individual domains altered MMP2 and -9 activity in X. laevis embryos. Gelatin zymography was used to measure changes in
MMP-2 and MMP-9 activity resulting from overexpression of 4 ng of TIMP-2 full-length
(T2FL), N-terminal (T2N), C-terminal (T2C), or TIMP-3 full-length (T3FL), N-terminal
(T3N), or C-terminal (T3C) mRNA constructs. Proteins were extracted from embryos at
developmental stage 30, following injection of each TIMP construct. Active MMP-9 (84
KDa) and MMP-2 (63 KDa) are visualized as bright bands against a dark background.
Densitometry readings were used to quantify and graph changes in MMP-9 (dark grey) and
MMP-2 (light grey) activities relative to control (uninjected) embryos. Graphed data is from
one representative experiment, where trends and relative levels were observed consistently in
at least 3 trials.
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2.3.7. Real-time PCR analysis of marker genes in post-TIMP construct injected embryos
To better understand the phenotypes I observed following overexpression of TIMP-2
or -3 or their individual domains, I performed quantitative real-time PCR on injected
embryos to look for changes in key genes associated with TIMP-2 and -3 activity.
Specifically, I assayed for changes in MMP-2 and -9 expression as well as for changes in
RECK and β1 integrin expression (Fig. 2.7 A and B). My results showed that none of the
TIMP constructs altered RECK or β1 integrin expression levels substantially. It is noteworthy
that neither T2C nor T2FL constructs resulted in substantial decreases in RECK expression
levels (though the trend was towards a decrease), as this relationship has previously been
demonstrated in mouse and human cell lines (Oh, Seo et al. 2004). However, previous
studies were carried out with homogenous cell populations in vitro, whereas embryos contain
many types of cells, only some of which may be able to bind to TIMPs and modulate RECK
expression. A more careful analysis must be carried out to examine the possibility of
localized changes in RECK or β1 integrin levels in response to TIMP signaling.
Although RECK expression remained largely unaltered, my results indicated that T2C
may have a role in mediating other important signaling events during X. laevis development.
Real-time PCR showed that the T2C construct resulted in dramatic decreases in MMP-2 and 9 expression (decreased 14 and 15 fold, respectively) compared with controls (Fig. 2.7 A).
As my zymography data indicated that MMP activity is upregulated at the time, this decrease
in transcript is puzzling. However, while increased MMP activity in vivo could be achieved
through the activation of existing pro-MMPs, the change in transcript levels may reflect a
cell signaling function of the T2C construct that is independent of the function of a native
whole TIMP molecule. As such, the embryo is responding to signals mediated by a protein
domain that is no longer linked to the usual activities of the entire molecule. Consequently,
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genes are regulated in a fashion that is not normal and thus, detrimental. The T2N construct
also decreased MMP-9 expression, however, only by about 4-fold, and T2FL showed
comparable results. The less marked changes in expression following injection with T2FL
and T2N constructs may be the result of an MMP-dependent regulatory feedback
mechanism, as injection of T3FL and T3N constructs resulted in comparable changes in
MMP-2 and -9 expression (Fig. 2.7 B). Since the T2C construct does not have any MMPinhibitory activity, the observed decreases in MMP-2 and -9 expression are likely due to an
MMP-independent TIMP-2 mediated signaling cascade. Indeed, recent research has shown
that the TIMP-2 C-terminal domain may be involved in a variety of cell signaling cascades,
including receptor tyrosine kinase (RTK), NF-κB, and cell proliferation pathways (Murphy,
Unsworth et al. 1993; Seo, Li et al. 2003; Sun and Stetler-Stevenson 2009). In addition, I
have unpublished data which showed that the T2C construct can bind to the surface of X.
laevis A6 cells, indicating that there is at least one potential cell surface binding partner for
the C-terminal domain of TIMP-2 to signal through in X. laevis. Interestingly, the unique
TIMP-2 C-terminal signaling cascade could be species specific as sequence analysis suggests
that this domain is less conserved than its N-terminal counterpart (Fig. 2.1; see appendix D
for table of PCR CT values).
In contrast, the T3C construct did not result in considerable changes in gene
expression (Fig. 2.7 B). This is consistent with the fact that I did not observe any large-scale
morphological changes in T3C injected embryos, and supports the conclusion that the Cterminal domain of TIMP-3 is likely only involved in mediating binding of TIMP-3 to
components of the ECM.
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Figure 2.7. Effect of full-length TIMP-2 or -3 and their N- and C-terminal domains on
transcript levels. Real-time PCR was used to measure the changes in transcript levels
following the injection of 4 ng of (A) TIMP-2 full-length (T2FL), N-terminal (T2N), or Cterminal (T2C), or (B) TIMP-3 full-length (T3FL), N-terminal (T3N), or C-terminal (T3C)
mRNA constructs into X. laevis embryos at the one cell stage. Changes in transcript levels
were measured relative to Ef-1α and normalized to control (uninjected) embryos. INTG Beta
1 represents β1 integrin. Results are based on the average of 3 independent sets of
experiments. Bars indicate SE (see appendix D for table of PCR CT values).
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2.4 Conclusions
Taken together, I observed that while the N- and C-terminal domains of TIMP-2 were
similar in their patterns of evolutionary conservation, the two domains differed in their
abilities to alter gene expression and MMP activity. The misregulation of either domain had
severe consequences on development, more so than the overexpression of full-length TIMP2. This suggested that both domains of TIMP-2 serve a unique function, one MMPdependent, one MMP-independent, where their function is mediated and moderated when
they are part of the whole TIMP-2 molecule. In contrast, the TIMP-3 domains differed in
their patterns of divergence, and the C-terminal domain had little effect on gene expression
or MMP activity. With TIMP-3, however, misregulation of the full-length molecule was
most detrimental, suggesting that the molecule works as a whole, and that there is little or no
MMP-independent function, at least at the developmental stages examined in this study.
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CHAPTER THREE
FUNCTIONAL CHARACTERIZATION OF TISSUE INHIBITOR OF
METALLOPROTEINASE -1 (TIMP-1) N- AND C-TERMINAL DOMAINS DURING
XENOPUS LAEVIS DEVELOPMENT
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M.A. and Damjanovski, S. (2013). Functional characterization of tissue inhibitor of
metalloproteinase-1 (TIMP-1) N- and C-terminal domains during Xenopus laevis
development. PlosOne manuscript ID: PONE-D-13-19519.” The text has been modified from
the original manuscript to adhere to formatting guidelines for this thesis. Experiments were
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3.1 Introduction
3.1.1. ECM dynamics in development
MMPs are important regulators of development due to their ability to cleave
structural components of the ECM, as well as secreted signaling molecules within the ECM,
leading to changes in both cell movement and cell signaling (Vu and Werb 2000). Controlled
inhibition of MMP activity is needed to prevent excessive ECM degradation, and is largely
carried out by TIMPs, as well as the cell surface MMP inhibitor, RECK (Nagase, Visse et al.
2006). Maintaining the proper balance between MMP activity and inhibition is necessary
during embryogenesis and facilitates developmental events including organogenesis and
angiogenesis (Liotta, Steeg et al. 1991; Blelloch and Kimble 1999), and disrupting this
balance can have deleterious effects (Zhang, Bai et al. 2003; Pickard and Damjanovski
2004). Inhibition of MMP-2 or -9, two potent ECM proteases, can lead to axial defects and
incomplete neural crest cell migration, respectively, while knockout of membrane-bound
MMP-14 (MT1-MMP) during mouse development is embryonic lethal (Zhou, Apte et al.
2000; Hasebe, Hartman et al. 2007; Monsonego-Ornan, Kosonovsky et al. 2012). Knockout
of RECK during development is also lethal due to defects in angiogenesis (Oh, Takahashi et
al. 2001). Additionally, my research has shown that overexpression of TIMP-2 and -3 during
Xenopus laevis development leads to axial and neural tube defects (Chapter 2) (Nieuwesteeg,
Walsh et al. 2012). Thus, disruption of activity levels in this proteolytic ECM remodeling
network is detrimental during development.

3.1.2. Structure and function of TIMPs
Although TIMPs are a family of only 4 secreted proteins (TIMP 1-4), together they
can inhibit all known MMPs by binding to MMPs in a 1:1 manner to block their proteolytic
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activity (Murphy 2011). As discussed in section 1.3.1., the four mammalian TIMPs share
similar domain structure and roughly 40% amino acid sequence similarity, including 12
conserved cysteine residues which result in the formation of 6 disulfide bonds (Nagase,
Meng et al. 1999). The structurally and functionally distinct N- and C-terminal domains of
TIMP proteins are each stabilized by 3 disulfide bonds (Nagase, Meng et al. 1999). The Nand C-terminal domain boundary is found between cysteines 6 and 7, in between which there
are only one or two amino acids (see Fig. 1.1, section 1.3.1). The N-terminal domain of a
TIMP is both necessary and sufficient for MMP inhibition, and sequesters MMP activity by
binding to the zinc active site found in the catalytic domain of all MMPs (Gomez, Alonso et
al. 1997). In contrast, the smaller C-terminal domain of TIMPs may influence cell behavior
in an MMP-independent manner through direct regulation of a number of cell signaling
pathways (Chirco, Liu et al. 2006). As previously discussed, characterization of cell surface
binding partners and specific signaling events involving TIMP C-terminal domains has been
carried out in vitro, where activation of a resultant signaling pathway varies with the specific
TIMP expressed, as well as the cell type each TIMP is expressed in (Bourboulia and StetlerStevenson 2010).

3.1.3. TIMP-1 overview
TIMP-1 was first identified for its erythroid potentiating activity, and as an inhibitor
of metalloproteinases (Docherty, Lyons et al. 1985; Gasson, Golde et al. 1985). Both the Nand C-terminal domains of TIMP-1 have now been well characterized in vitro. The two
domains of TIMP-1, as well as of the other TIMPs, have the ability to fold and function
autonomously in vitro (Gomez, Alonso et al. 1997; Bahudhanapati, Zhang et al. 2011;
Nieuwesteeg, Walsh et al. 2012). TIMP-1 can inhibit MMP-2 and -9, which are two powerful

!

79

ECM proteases that cleave abundant ECM components (Nagase, Visse et al. 2006; Shah,
Shukla et al. 2009). Through its C-terminal domain, TIMP-1 has been linked to regulation of
specific cell signaling pathways. TIMP-1 has been shown to promote cell proliferation
(Hayakawa, Yamashita et al. 1992), although the receptor-mediated events involved in this
pathway remain unidentified. More recently, TIMP-1 has been associated with inhibition of
apoptosis in several human cell lines (Guedez, Stetler-Stevenson et al. 1998; Li, Fridman et
al. 1999). TIMP-1 may also increase the abundance of cellular survival and differentiation
factors, and this activity has been linked to association of TIMP-1 with cell-surface CD63
and β1 integrin (discussed in section 1.6.2.) (Guedez, Stetler-Stevenson et al. 1998;
Berditchevski and Odintsova 1999; Guedez, Mansoor et al. 2001; Jung, Liu et al. 2006). To
date, however, the unique activities of the individual TIMP-1 domains have not been well
characterized in vivo, and the specific roles of the two domains as they pertain to
development remain unknown.

3.1.4. Summary and experimental approach
I have previously preformed a series of domain specific overexpression experiments,
which suggested that the TIMP-2 and -3 N- and C-terminal domains may have specific
MMP-dependent and independent functions, respectively, during embryogenesis in X. laevis
(Chapter 2) (Nieuwesteeg, Walsh et al. 2012). In the present study, I used a similar approach
to characterize the unique functions of the TIMP-1 N- and C-terminal domains during early
X. laevis development. Here I show that the TIMP-1 C-terminal domain can act
autonomously to alter gene expression and MMP levels in X. laevis embryos, and that axial
and head defects resulting from C-terminal domain overexpression are different than those
observed with the N-terminal domain.
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3.2 Materials and Methods
3.2.1. Cloning of X. laevis TIMP-1
X. laevis TIMP-1 was cloned using primers designed from unannotated X. laevis
clone AAI41767.1. Primers used were Forward: 5’-GACAGAAGGACTGCCCAGCC-3’
and Reverse: 5’-CAAAACACTTCTCCTTCGAG-3’. Xenopus laevis TIMP-1 was isolated
from total cDNA from stage 35 embryos using SuperScriptTM Reverse Transcriptase (Life
Technologies) with Platinum® Taq DNA Polymerase High Fidelity (Life Technologies). The
full-length TIMP-1 amplicon was cloned into the pCR®II-TOPO vector (Life Technologies),
and the sequence of full-length X. laevis TIMP-1 was confirmed at the Robarts Research
Institute DNA Sequencing Facility at the University of Western Ontario, and submitted to
Genbank as: KF018236 (see Appendix A for coding sequence).

3.2.2. Comparison of amino acid identity between vertebrate TIMP-1 N- and C-terminal
domains
Sequence alignments and amino acid sequence identity were performed using
ClustalW2 analysis software from the European Bioinformatics Institute website
(http://www.ebi.ac.uk/Tools/clustalw2/index.html), using default settings. Phylogenetic
comparisons were performed using MEGA 5.2.1. software to construct a neighbour-joining
tree with a bootstrap of 1000. Accession numbers of known full-length TIMP-1 proteins were
as follows: Human (Homo sapiens) NP_003245.1; Mouse (Mus musculus) AAH51260.1; Rat
(Rattus norvegicus) EDL97726.1; Cow (Bos taurus) AAP44413.1; Horse (Equus caballus)
NP_001075984.1; Rabbit (Oryctolagus cuniculus) AAW79053.1; Shark (Callorhinchus
milii) AFK11387.1; Newt (Notophthalmus viridescens) ABB88702.1.
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3.2.3. Animals
Adult X. laevis were purchased from Ward’s Natural Science (Rochester, NY), and
fertilized, reared and housed as described in section 2.2.2.

3.2.4. Generation of TIMP-1 mRNA constructs for microinjection
PCR was used to generate full-length (T1FL), N-terminal (T1N) or C-terminal (T1C)
TIMP-1 HA-tagged constructs using the full-length clone as a template. Briefly, all TIMP-1
constructs (T1FL, T1N, T1C) were HA-tagged on their C-terminal end. The C-terminal
domain construct (T1C) was engineered to include its appropriate secretory signal sequence
through a two-step PCR process. Primers were as follows: T1FL forward 5’AGATCTATGTTGTACCTTGTGGTTGTG

-3’

and

T1FL

reverse

5’-

CAGTCTGCTGCCACAACACAATACCCATACGATGTTCCAGATTACGCTACTAGT 3’; TIN forward 5’- AGATCTATGTTGTACCTTGTGGTTGTG and T1N reverse
GTGTATCGCAAAGCCTGTTCCTACCCATACGATGTTCCAGATTACGCTACTAGT3’; T1C signal sequence forward 5’-AGATCTATGTTGTACCTTGTGGTTGTG-3’ and T1C
signal

sequence

reverse

link

5’-

CTCAGCCAGGAGGTGTTGGGGTGCAACATCGTCCCCTGCTAT-3’, and C-terminal
domain forward link 5’-TGCAACATCGTCCCCTGCTAT-3’ and C-terminal domain
reverse

5’-

CAGTCTGCTGCCACAACACAATACCCATACGATGTTCCAGATTACGCTACTAGT3’. Following PCR amplification, the sequence of all amplicons was verified. All TIMP-1
constructs were subsequently ligated into the EcoRV/SpeI restriction sites of the T7TS
plasmid. An mMessage mMachine in vitro transcription kit was used with T7 RNA
polymerase (Ambion) to synthesize stable capped, poly(A)-tailed mRNA transcripts that
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were dissolved in filtered water. mRNA was quantified using Nanovue spectrophotometer
(GE), and its integrity was assessed using 1% agarose gel electrophoresis. GFP mRNA was
generated and quantified in a similar manner from a proven T7TS-GFP construct plasmid
(Walsh, Cooper et al. 2007).

3.2.5. mRNA microinjection
Embryos at the 1 cell stage were injected with 4 ng of TIMP-1 full-length, Nterminal, or C-terminal (T1FL, T1N, T1C) mRNA constructs in a volume of 2.3 nl as
described in section 2.2.5. Embryos that were dead or abnormal 2 hr post-injection were
removed, and the remaining embryos (representing the 100% being monitored) were
observed for phenotypic abnormalities. The percent of normal embryos (no visible defects)
was quantified for two days following injection (until stage 30 in development). Mean values
were obtained from 3 independent sets of experiments.

3.2.6. Semi-quantitative RT-PCR analysis
Semi-quantitative RT-PCR analysis was used to examine changes in proteolytic gene
expression patterns, or to confirm upregulation of TIMP-1 following injection with T1FL,
T1N, or T1C constructs compared to control embryos. Total RNA was extracted from
injected and control embryos using RNeasy Mini Kit (Qiagen) and 1 µg RNA was reverse
transcribed using qScriptTM cDNA Supermix (Quanta Bioscienes). PCR was carried out using
KAPA Taq PCR Kit (KAPA Biosystems) and Eppendorf Thermal Cycler. The cycling
conditions were as follows: initial denaturation, 95°C for 2 min, followed by 28 cycles of the
following: denature 95°C 30 sec, anneal 55°C 30 sec, extend 72°C 30 sec. Primers, based on
the X. laevis sequences, were as follows: Ef-1α 5’-TGTTGGCAGAGTGGAGACTG-3’ and
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5’-GGCCAAGTGGAGGATAGTCA-3’; TIMP-2 5’-AGGTAAAGCCGATGGTGATG-3
and 5’-GCCTGTCGTCCGTTTATGTT-3’; TIMP-3 5’-TTCCAAGAACGAGTGCCTCT-3’
and 5’-GGGATCCGTGGTGTTTATTG-3; RECK 5’GGATGTTTACAGGTCTACCC-3’
and

5’

GGCTCTGTTCCTCCAAAGAT-3’;

MT1-MMP

5’-

CTATGAGGCGATTCGGAGAG-3’ and 5’-GCCACCAGGAACAGATCATT-3’; MMP-2
5’-TGATTCTGGTCGCTCAGATG-3’ and 5’-CTTGTTTCCCAGGAAGGTGA-3’; MMP-9
5’-AGGACCATGGGGATCCTTAC-3’ and 5’-AACACAAGGCTGCCCATTAC-3’; T1FL
and T1C 5’-ATGTTGTACCTTGTGGTTGT-3’ and 5’-TTATTGTGCTGTGCAGCAG-3’;
T1N 5’- ATGTTGTACCTTGTGGTTGT-3’ and 5’-GGAACAGGCTTTGCGATACAC-3’.

3.2.7. Protein preparations and Western blotting
Stage 30 embryos injected with T1FL, T1N or T1C mRNA constructs, or uninjected
controls, were subject to protein extraction. Briefly, 10 embryos were lysed and sonicated in
100 µl modified RIPA buffer (150 mM NaCl, 50 mM Tris (pH 8.0), 1.0% NP-40, 0.5%
sodium deoxycholate, 0.1% SDS, 10µl/ml HaltTM Protease Inhibitor Cocktail (Thermo
Scientific) and 10 µL/ml HaltTM Phosphatase Inhibitor Cocktail (Thero Scientific)) and
lysates were centrifuged at 15,000 g for 25 min at 4°C. The supernatant was removed and
protein was quantified using BCA protein assay kit (Thermo Scientific) according to
manufacturer’s instructions. Electrophoresis and Western blotting was performed as
previously described in section 2.2.6. Primary antibodies used were rabbit anti-HA antibody
(1:1000 dilution; Santa Cruz) or mouse anti-β-actin antibody (1:1000 dilution; Santa Cruz).
Secondary antibodies used were goat anti-rabbit HRP (1:5000 dilution; Life Technologies) or
goat anti-mouse HRP (1:5000 dilution; Bio-Rad). Western blots were visualized and
photographed using Bio-Rad Quantity One 4.4.0 software.
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3.2.8. Zymography and reverse zymography
12.5 µg of protein (as extracted in section 3.2.7.) from T1FL, T1N or T1C injected
embryos, or uninjected control embryos was diluted 1:1 with 2X SDS-loading buffer (0.5 M
Tris-HCl, pH 6.8, 10% SDS, 2.5 % glycerol, 1% Bromophenol Blue). For zymography,
protein samples were electrophoresed on a 1% gelatin, 10% polyacrylamide gel. For reverse
zymography, protein was electrophoresed on a 1% gelatin, 15% polyacrylamide gel copolymerized with MMP-conditioned media from Hs578t cells according to Hawkes et al.
(2010). Hs578t cells were chosen for their ability to secrete high levels of MMPs, particularly
MMP-2 and -9. For both zymography and reverse zymography, gels were electrophoresed in
1X zymogram running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS), followed by in-gel
renaturation for 30 min at room temperature in renaturing solution (2.5%Triton X-100).
Substrate cleavage was carried out by incubating gels in zymogram developing buffer (pH
7.5, 50 mM Tris, 200 mM NaCl, 5 mM CaCl2 (anhydrous), 0.02% Brij-35) for 48 hr at 37°C.
For zymography, MMP activity was visualized as clear bands against blue background after
staining with 0.5% Coomassie blue (Bio-Rad). For reverse zymography, TIMP activity was
visualized as dark bands against light background after staining with 0.5% Coomassie blue
(Bio-Rad). Gels were visualized and photographed, and densitometry was performed using
Bio-Rad Quantity One 4.4.0 software.

3.2.9. Statistical analysis
All statistical analysis was performed using the IBM SPSS Statistic 19 program.
Results were presented as mean ± SE. Statistical significance was determined using one-way
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ANOVA variance analysis and Dunnett’s multiple comparisons tests. Differences were
considered statistically significant when p < 0.05.

3.3 Results
3.3.1. Amino acid sequence conservation of vertebrate TIMP-1 N- and C-terminal domains
A direct amino acid sequence comparison of the individual TIMP-1 N- and Cterminal domains between species has not previously been reported. Current full-length
TIMP-1 protein sequences were identified, which thus far have only been confirmed in
vertebrates. To investigate whether the unique functions of these domains may be concurrent
with their patterns of evolutionary conservation, I cloned X. laevis TIMP-1 (GenBank:
KF018236) and compared its N- and C-terminal domains with known mammalian and nonmammalian TIMP-1 sequences. The N-terminal domain of X. laevis TIMP-1 was more
highly conserved than its C-terminal domain with 7 of 9 vertebrate species analyzed (Fig. 3.1
A). In general, the N-terminal domains of all species were more highly conserved than the Cterminal domains, with the exception of horse and cow, where the C-terminal domains were
more highly conserved between species (Fig. 3.1 A). Phylogenetic analysis of TIMP-1 Nand C-terminal domains with other vertebrate species showed the two domains follow a
different evolutionary trend, as the branching patterns of the two trees differed, indicating
that both domains evolved under different selective pressures (Fig. 3.1 B and C).
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Figure 3.1. Evolutionary conservation of TIMP-1 N- and C-terminal domains differed.
(A) Sequence analysis comparing amino acid sequence identity of X. laevis TIMP-1 N- and
C-terminal domains versus known vertebrate species. Light purple boxes represent species
whose N-terminal domains were more highly conserved with X. laevis TIMP-1 than their Cterminal domains. Light pink boxes represent species whose C-terminal domains were more
highly conserved with X. laevis TIMP-1 than their N-terminal domains. Blue boxes represent
species with equal conservation with both X. laevis TIMP-1 N- and C-terminal domains. (B)
Phylogram representation of sequence divergence among TIMP-1 N-terminal domains as
generated by MEGA 5.2.1. software. (C) Phylogram representation of sequence divergence
among TIMP-1 C-terminal domains as generated by MEGA 5.2.1. software.
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3.3.2. TIMP-1 mRNA and protein was upregulated in X. laevis embryos following ectopic
expression of TIMP-1 constructs
To characterize the unique roles of the TIMP-1 N- and C-terminal domains during
development, I have performed a series of domain specific overexpression experiments. For
this purpose, I generated full-length, N-terminal and C-terminal HA-tagged TIMP-1 mRNA
constructs (T1FL, T1N and T1C, respectively), which were injected into newly fertilized X.
laevis embryos (1 cell stage). Total RNA was collected from injected and control embryos 1
day post-fertilization (stage 15), and RT-PCR analysis was used to verify levels of TIMP-1
mRNA transcripts in injected embryos compared to controls (Fig. 3.2 A). Uninjected control
embryos contained much lower levels of TIMP-1 mRNA compared to T1FL, T1N or T1C
injected embryos, which showed relatively equal but elevated levels of TIMP-1 relative to Ef1α (loading control; Fig. 3.2 A). By two days post-fertilization (stage 30), each HA-tagged
TIMP-1 construct was still present and detectable on Western blot via HA antibody in
injected embryos (Fig. 3.2 B), indicating that all constructs produced stable protein products.
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Figure 3.2. Confirmation of full-length, N-terminal or C-terminal TIMP-1 constructs
overexpressed in X. laevis embryos. 4 ng of mRNA coding for full-length (T1FL), Nterminal (T1N) or C-terminal (T1C) TIMP-1 constructs was microinjected into X. laevis
embryos at the 1 cell stage. (A) Overexpression of TIMP-1 mRNA as shown by RT-PCR
analysis. mRNA was isolated from stage 15 embryos. Control (uninjected) embryos
expressed TIMP-1 at very low levels. Primers specific to each construct were used to confirm
mRNA levels of T1FL (678 bp), T1N (453 bp) and T1C (252 bp). Ef-1α loading control is
shown below (479 bp). (B) Levels of TIMP-1 constructs as detected by Western blot
analysis. All constructs are HA-tagged. Protein was isolated from stage 30 embryos. AntiHA antibodies were used to confirm expression of each construct at the protein level (T1FL
= 26KDa, T1N = 18KDa, T1C = 12 KDa). No HA was detected in control uninjected
embryos. β-actin was used as protein loading control.
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3.3.3. Overexpression of full-length, N-terminal and C-terminal TIMP-1 constructs
produced unique developmental phenotypes
Following injection of each TIMP-1 construct, embryos were monitored for gross
morphological changes in development for 2 days post-fertilization (until developmental
stage 30). Uninjected control embryos were morphologically normal (Fig. 3.3 A). By stage
30 in development, embryos overexpressing full-length (T1FL) or N-terminal (T1N) TIMP-1
displayed relatively normal anterior (head) development with posterior axis defects. T1FL
and T1N injected embryos did, however, display a bent axis phenotype along with truncated
anterior/posterior axes compared to controls (Fig. 3.3 B and C, respectively). Embryos
overexpressing C-terminal TIMP-1 (T1C) also had truncated axis defects compared to
controls, as well as other developmental abnormalities. Chiefly, T1C injections resulted in
head defects, and failure of the neural tube to close (Fig. 3.3 D; see appendix C for additional
images). Generally, overexpression of T1C resulted in more severe phenotypic consequences
than overexpression of T1FL or T1N constructs.
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Figure 3.3. Phenotypic effects of overexpression of full-length, N-terminal or C-terminal
TIMP-1 constructs. Following injection, photographs were taken of representative embryos
at stage 30. (A) Control (uninjected) embryos were phenotypically normal. Microinjection of
T1FL (B) and T1N (C) constructs both resulted in normal anterior (head) development but
truncated posterior axes. (D) Microinjection of T1C constructs resulted in lack of head
structures, other head defects, and neural tube closure failure. Panel A magnification is lower
than in B C and D. Actual size of all embryos is 1 mm in diameter. Images are of
representative embryos where results were consistent in at least 3 independent sets of
experiments, and a minimum of 100 embryos were injected and monitored for each replicate.
See appendix C for additional images.
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3.3.4. Overexpression of full-length and C-terminal TIMP-1 resulted in increased
embryonic lethality compared to overexpression of N-terminal TIMP-1
To compare and measure the effects of overexpressing full-length vs. N-terminal or
C-terminal domain TIMP-1 during X. laevis development, T1FL, T1N and T1C injected
embryos were monitored for 48 hours following fertilization, and the percent of normal
embryos (embryos that were alive and morphologically normal) was determined and
quantified at stage 15 (1 day post-fertilization) and stage 30 (2 days post-fertilization). More
than 90% of control embryos, or embryos injected with GFP mRNA, developed normally
during this time period (Fig. 3.4). Overexpression of all TIMP-1 constructs resulted in
increased lethality compared to controls. By stage 15, all constructs resulted in an
approximate 20% decrease in normal embryo numbers compared to controls (Fig. 3.4). By
stage 30, 66% of T1N injected embryos developed normally, whereas T1FL and T1C
constructs were slightly more detrimental, with only 58% and 55% normal development,
respectively (Fig. 3.4).
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Stage

Figure 3.4. Overexpression of all three TIMP-1 constructs led to abnormal development
and death. Following injection of mRNA constructs at the 1 cell stage, embryos were scored
for a normal (no visible defect) phenotype at stage 15 and 30. Dead and abnormal embryos
were counted as containing morphological defects. The graph shows the percentage of
normal embryos following injection of GFP mRNA (GFP), or full-length (T1FL), N-terminal
(T1N) or C-terminal (T1C) TIMP-1 mRNA constructs at the given stages. Control embryos
are uninjected. Results are based on 3 independent sets of experiments, bars indicate SE.
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3.3.5. Overexpression of full-length, N-terminal or C-terminal TIMP-1 constructs in X.
laevis embryos altered expression of proteolytic genes
To examine the roles of full-length, N-terminal or C-terminal TIMP-1 in regulating
ECM remodeling in vivo, I investigated the expression patterns of hallmark genes involved in
regulating ECM proteolysis following microinjection with T1FL, T1N or T1C constructs into
X. laevis embryos. mRNA was collected from embryos at stage 30 in development, as I had
observed specific and unique morphological defects at this time point following injection of
each construct (see Fig. 3.3). Semi-quantitative RT-PCR analysis, was used to assay for
changes in mRNA levels of the MMP inhibitors TIMP-2, TIMP-3 and RECK, as well as the
MMPs MMP-2, -9 and MT1-MMP. All of these genes have previously been shown to be
important regulators of ECM remodeling during development (Hasebe, Hartman et al. 2007;
Chandana, Maeda et al. 2010; Monsonego-Ornan, Kosonovsky et al. 2012; Nieuwesteeg,
Walsh et al. 2012). mRNA levels were normalized to Ef-1α and compared to control
(uninjected) embryos.
Overexpression of T1FL and T1C significantly decreased TIMP-2 mRNA relative to
controls (Fig. 3.5 A, p < 0.05). This decrease was most significant following overexpression
of TIC (p < 0.01); whereas, T1N did not significantly alter TIMP-2 compared to control
embryos. Levels of TIMP-3 mRNA were not significantly altered compared to control
embryos following treatment with of any of the TIMP-1 constructs (Fig. 3.5 B). RECK
expression was significantly decreased relative to controls following injection of T1FL (p <
0.05) and T1C (p < 0.01, Fig. 3.5 C) constructs.
MMP-2 mRNA levels were significantly decreased compared to controls following
overexpression of all constructs (T1FL, T1N and T1C; Fig. 3.6 A, p < 0.01). Following
injection of T1C, MMP-9 mRNA was significantly decreased (Fig. 3.6 B, p < 0.05). No
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significant change in MMP-9 mRNA levels was observed in embryos injected with T1FL or
T1N constructs (Fig. 3.6). Similarly, levels of MT1-MMP mRNA were not altered relative to
control embryos following overexpression of any TIMP-1 constructs (Fig. 3.6 C).
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Figure 3.5. Effect of overexpression of full-length, N-terminal or C-terminal TIMP-1 on
mRNA levels of MMP inhibitors. Semi-quantitative RT-PCR analysis was used to measure
changes in mRNA levels of (A) TIMP-2, (B) TIMP-3 and (C) RECK at stage 30, following
microinjection of 4 ng of TIMP-1 full-length (T1FL), N-terminal (T1N), or C-terminal (T1C)
constructs into X. laevis embryos at the 1 cell stage. In each case mRNA levels were
measured relative to Ef-1α. The results are presented as mean ± SE from 3 independent
experiments. Asterisks represent a significant difference of * p < 0.05 and ** p < 0.01, all
versus control (CONT; uninjected) embryos, as analyzed by one-way ANOVA and Dunnett’s
multiple comparisons test.
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Figure 3.6. Effect of overexpression of full-length, N-terminal or C-terminal TIMP-1 on
mRNA levels of MMPs. Semi-quantitative RT-PCR analysis was used to measure changes
in mRNA levels of (A) MMP-2, (B) MMP-9 and (C) MT1-MMP at stage 30, following
microinjection of 4 ng of TIMP-1 full-length (T1FL), N-terminal (T1N), or C-terminal (T1C)
constructs into X. laevis embryos at the 1 cell stage. In each case mRNA levels were
measured relative to Ef-1α. The results are presented as mean ± SE from 3 independent
experiments. Asterisks represent a significant difference of * p < 0.05 and ** p < 0.01, all
versus control (CONT; uninjected) embryos, as analyzed by one-way ANOVA and Dunnett’s
multiple comparisons test.
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3.3.6. Overexpression of all TIMP-1 constructs decreased the amount of active MMP-2
and -9
To further understand how the individual TIMP-1 domains affect the proteolytic
network in vivo, gelatin zymography was used to measure changes in the amounts of active
MMP-2 and -9 in T1FL, T1N or T1C injected embryos relative to control (uninjected)
embryos.

Embryos injected with T1FL, T1N and T1C constructs showed significantly

decreased levels of active MMP-2 relative to control embryos (Fig. 3.7 A, p < 0.01).
Injection of all three TIMP constructs also resulted in significantly decreased levels of active
MMP-9 relative to controls (Fig. 3.7 B, p < 0.01); however, interestingly, this trend was most
pronounced following injection of the T1C construct.
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Figure 3.7. Zymography demonstrated altered levels of active MMP-2 and MMP-9
following overexpression of TIMP-1 constructs. Embryos were injected at the 1 cell stage
with 4 ng of mRNA coding for full-length (T1FL), N-terminal (T1N) or C-terminal (T1C)
constructs, and protein was isolated from stage 30 embryos. Gelatin zymography was used to
measure changes in (A) MMP-2 and (B) MMP-9 activity. Zymogram (top) is representative
of one experiment. Graphs represent quantification zymograms, and data is presented as
mean ± SE from 3 independent experiments. ** p < 0.01, all versus control (CONT;
uninjected) embryos, as analyzed by one-way ANOVA and Dunnett’s multiple comparisons
test.
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3.3.7. Only full-length and N-terminal TIMP-1 constructs directly inhibited MMP activity
To validate the MMP-inhibitory activity of the full-length and N-terminal TIMP-1
constructs, and also to confirm that the C-terminal TIMP-1 construct could not directly
inhibit MMPs, I performed reverse zymography. Reverse zymography is a modification of
traditional zymography by incorporating gelatin into the gel matrix as well as conditioned
media from cancer cells as a source of MMP-2 and -9 activity. Subsequently, the proteins of
interest are separated within the gel by molecular weight. The gelatin is degraded by MMPs
in the matrix, except for where inhibited by active TIMPs. TIMP activity is visualized as a
dark band after staining with Coomassie Blue (Hawkes, Li et al. 2010), representing a
protected band corresponding to the molecular weight of the active construct. Protein was
isolated from injected stage 30 embryos, and analyzed for MMP-inhibitory activity
corresponding to T1FL, T1N and T1C construct sizes. T1FL and T1N constructs showed
MMP-inhibitory activity at the expected sizes of 26 KDa and 18 KDa, respectively (Fig. 3.8,
white arrows), whereas the T1C construct was not able to inhibit MMPs at the expected size
of 12 KDa (Fig. 3.8, black arrow). Control embryos showed a faint band corresponding to
endogenous TIMP-1 (26 KDa), which was upregulated in T1FL injected embryos (Fig. 3.8).
Higher molecular weight bands are not indicative of TIMP activity, but represent proteins
that are present at sufficiently high concentrations to be stained by Coomassie Blue, due to
the large amount of yolk present in X. laevis embryos (Hawkes, Li et al. 2010).
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Figure 3.8. Reverse zymography demonstrated full-length and N-terminal, but not Cterminal TIMP-1, can directly inhibit MMP activity. Embryos were injected at the 1 cell
stage with 4 ng of mRNA coding for full-length (T1FL), N-terminal (T1N) or C-terminal
(T1C) TIMP-1 constructs, and protein was isolated from stage 30 embryos. MMP-inhibitory
activity is represented by dark bands. White arrows indicate the location of the expected
inhibitory bands corresponding to the T1FL (26 KDa) and T1N (18 KDa) constructs,
respectively. A black arrow represents the position of the T1C (12 KDa) construct, which
cannot inhibit MMP activity as demonstrated by the presence of a light band. Higher nonspecific molecular weight bands at the top of the gel help demonstrate equal protein loading.
Such bands are not indicative of TIMP activity but are the result of high concentrations of
proteins that stain deeply with Coomassie Blue. This is seen with many complex tissues (Van
Wart and Birkedal-Hansen 1990) and is due to the very abundant yolk and other storage
proteins that are found in the embryo.
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3.4 Discussion
ECM remodeling is a key process involved in regulating tissue growth and
morphogenesis during development. Maintaining the appropriate balance between MMPs
and their inhibitors (TIMPs and RECK) is absolutely essential for normal development, and
disruption of this balance leads to defects in neurulation, organogenesis and angiogenesis
(Liotta, Steeg et al. 1991; Blelloch and Kimble 1999; Monsonego-Ornan, Kosonovsky et al.
2012). Our understanding of the regulation of this proteolytic network has been convoluted
by the discovery that TIMP proteins have both MMP-inhibitory activity as well as MMPindependent cell signaling activity (Lambert, Dasse et al. 2004). With recent research on
TIMP C-terminal domains demonstrating their roles in apoptosis, cell proliferation, and cell
migration pathways, the functions of the TIMP C-terminal domains are becoming
increasingly studied in vitro (Hayakawa, Yamashita et al. 1992; Guedez, Stetler-Stevenson et
al. 1998; Li, Fridman et al. 1999; Oh, Seo et al. 2004). At the present time there has been
comparatively little research characterizing the roles of the N- and C-terminal TIMP domains
in vivo, particularly as they pertain to development. My research has previously examined the
specific functions of the N- and C-terminal domains of TIMP-2 and -3 during X. laevis
development, and found that the two domains have unique functions when overexpressed
individually in X. laevis embryos (Chapter 2) (Nieuwesteeg, Walsh et al. 2012). To date,
there has been no comparison of the unique functions of TIMP-1 N- and C-terminal domains
in a developmental context. Here I used mRNA overexpression to examine the role of fulllength TIMP-1 versus the roles of its individual N-terminal and C-terminal domains during
early X. laevis development.
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3.4.1. TIMP-1 N-terminal domains were more highly conserved with other vertebrates than
their C-terminal domains
To examine whether the distinct functions of the two TIMP-1 domains are reflected
in their evolutionary conservation, I identified and compared amino acid sequence identities
of the X. laevis TIMP-1 N- and C-terminal domains to other known vertebrate TIMP-1
sequences. I found that the TIMP-1 N-terminal domains were more highly conserved than
their C-terminal domains among most species analyzed, with the exception of the large
mammals, horse and cow, in which the C-terminal domains were more highly conserved
(Fig. 3.1 A). Since the catalytic domains of MMPs are highly conserved between species, it
is not surprising that TIMP-1 N-terminal MMP-inhibitory domains are also well conserved
(Van Wart and Birkedal-Hansen 1990). I have previously shown that the TIMP-2 N-terminal
domains were also more highly conserved across species than their C-terminal domains,
whereas for TIMP-3, I found the C-terminal domains were more highly conserved (Chapter
2, sections 2.3.1. and 2.3.2.) (Nieuwesteeg, Walsh et al. 2012). My findings suggest TIMP-1
may behave more like TIMP-2 than TIMP-3 with respect to MMP inhibition. Indeed, TIMP3 is unique in that it is a good inhibitor of the ADAM family of proteases (Rapti, Atkinson et
al. 2008). Additionally, TIMP-3 is sequestered away from the cell surface, whereas TIMP-1
and -2 function in a pericellular manner (Yu, Yu et al. 2000). While the TIMP-1 N-terminal
domain is more conserved than the C-terminal domain, phylogenetic analysis of sequence
divergence between vertebrate N- and C-terminal domains showed that the evolutionary
patterns are different, suggesting that both domains evolved under unique selective pressures
(Fig. 3.1 B and C). This suggests that functional roles of each domain are not the same.
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3.4.2. Overexpression of the TIMP-1 C-terminal domain resulted in detrimental
developmental defects
To examine differences in the in vivo roles of the TIMP-1 N- and C-terminal domains
I generated and overexpressed full-length, N- and C-terminal TIMP-1 mRNA constructs in X.
laevis embryos (T1Fl, T1N an T1C, respectively). Injection of embryos with T1C resulted in
more embryonic death than injection with T1FL or T1N (Fig. 3.4). Consistent with this
observation, overexpression of T1C also resulted in more severe developmental defects in
embryos at stage 30 in development, with these embryos showing head and neural tube
defects, as well as truncated axes. In comparison, T1FL and T1N injected embryos showed
normal head development but truncated anterior-posterior axes (Fig. 3.3), indicating that the
TIMP-1 C-terminal domain may contribute to unique functions in development separate from
the N-terminal domain.

3.4.3. The TIMP-1 C-terminal domain altered the ECM proteolytic network independent of
MMP inhibition
In order to further investigate the roles of the two TIMP-1 domains, RT-PCR analysis
was used to examine changes in mRNA levels of associated genes known to be involved in
the regulation of ECM remodeling. No changes were detected in levels of TIMP-3 or MT1MMP mRNA relative to control embryos, following injection with full-length, N-terminal or
C-terminal TIMP-1. This is consistent with previous work, which showed that association of
TIMP-1 with MT1-MMP is exceptionally poor (Hamze, Wei et al. 2007). In contrast, TIMP2 and RECK mRNA decreased compared to controls following injection of embryos with
T1FL or T1C; however, these decreases were most significant with T1C (Fig. 3.5). This
supports the concept that the C-terminal domain has the ability to regulate developmental
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events independent from the N-terminal domain, presumably through cell surface receptormediated signaling pathways.
Similarly, overexpression of T1C resulted in the most marked decreases in amounts
of MMP-2 and -9 mRNA compared to control embryos; although, in the case of MMP-2,
ectopic expression of all three constructs significantly decreased MMP-2 mRNA (Fig. 3.6).
These results were consistent with the zymography data, which showed the amounts of active
MMP-2 and -9 proteins followed the same trends as the RT-PCR analysis (Fig. 3.7).
Decreases in MMP-2 and -9 protein and mRNA may be partially due to a regulatory
feedback mechanism in the proteolytic network which occurs from direct catalytic inhibition
of MMPs by the N-terminal TIMP-1 domain, as T1N overexpression significantly decreased
MMP-2 mRNA and MMP-2 protein compared to control embryos. My results suggest,
however, that the C-terminal domain of TIMP-1 has the ability to regulate MMP mRNA and
protein levels independent from the N-terminal domain. Reverse zymography using MMPconditioned media from Hs578t cells showed that TIC constructs cannot directly inhibit
MMP activity (Fig. 3.8), yet overexpression of T1C resulted in the most significant decrease
in MMP-9 mRNA as well as a pronounced decrease in MMP-9 protein compared to control
embryos (Fig. 3.6 and 3.7). Although the mechanism of action of the TIMP-1 C-terminal
domain is still unknown, TIMP-1 has previously been shown to bind to cell surface receptors
on both fibroblasts and MCF-7 breast cancer cells, which resulted in translocation of TIMP-1
into the cell (Zhao, Li et al. 1998; Hamze, Wei et al. 2007). Taken together with the
emerging discoveries of new cell surface binding partners for TIMP-1, and its MMPindependent roles in cell signaling (Stetler-Stevenson 2008), it is possible that the C-terminal
domain of TIMP-1 may function to regulate expression of proteolytic genes through a
signaling mechanism that is separate from the N-terminal domain MMP-inhibitory activity.
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3.4.4. Concluding remarks
In summary, this research characterized in vivo the unique role of the TIMP-1 Cterminal domain. In vitro studies have demonstrated new roles for the TIMP C-terminal
domains in cell signaling. Additionally, disease models have highlighted the emerging
significance of the C-terminal TIMP domains in regulating the proteolytic network, as
synthetic MMP inhibitors designed to mimic TIMP N-terminal domains failed as an anticancer therapy to block metastasis associated with upregulated MMP activity (Brown 1998).
Here I have shown for the first time in vivo that the TIMP-1 C-terminal domain has an
independent role in regulating the proteolytic network during development, at a time when
this network is both complex and tightly regulated. I have no direct evidence as to the
mechanisms through which the individual ectopic domains are manifesting developmental
anomalies; however, there is evidence that feedback is involved as disruption of the
proteolytic network was compensated for in the embryo by changes in the levels of key
genes. Further, while there is no evidence that nascent TIMP-1 is cleaved into its individual
domains, my research suggests that the functions of the TIMP-1 N- and C-terminal domains
depend on the affinities of the individual domains for their binding partners, as well the
stoichiometric levels of TIMP-1 relative to secreted MMPs and cell surface receptors.
Further in vivo studies are needed to fully investigate whether there is preferential binding of
either domain in the context of abundant active MMPs and/or cell surface receptors.
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CHAPTER 4
ANALYSIS OF THE EFFECTS OF TIMP-1, -2 AND -3 N- AND C-TERMINAL
DOMAINS ON SIGNALING MARKERS DURING X. LAEVIS DEVELOPMENT
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4.1 Introduction
Although TIMPs were originally identified and characterized based on their abilities
to bind to and inhibit MMPs, it is now acknowledged that TIMPs are multifunctional
proteins, which can have pleiotropic effects on ECM remodeling and cell behavior. While the
TIMP N-terminal domains have been shown to impede MMP activity in many cell types and
model organisms, their C-terminal domains have demonstrated cell signaling activity in
specific cell lines in vitro. Characterization of TIMP C-terminal domain function has been
difficult as their roles in cell signaling vary, not only between the different TIMPs, but also
depending on the cell line under study (Stetler-Stevenson 2008). The seemingly contradictory
roles of TIMPs in up-regulating or down-regulating apoptosis and cell proliferation pathways
indicates that TIMPs may have cell or tissue-specific roles, where TIMP function may
depend on both the availability of cell surface receptors and the stoichiometry of free TIMPs
and MMPs within the ECM.

4.1.1. TIMPs in cell signaling
As discussed in previous chapters, in vitro studies have linked TIMPs to induction or
inhibition of apoptosis and cell proliferation pathways, as well as to upregulation of the cell
surface MMP inhibitor, RECK. TIMP-1 in particular has been shown to inhibit apoptosis in
Burkitt’s lymphoma cell lines, and this inhibition was demonstrated to occur through the
TIMP-1 C-terminal domain binding to the CD63-β1-integrin complex in MCF10A cells
(section 1.6.2) (Guedez, Stetler-Stevenson et al. 1998; Berditchevski and Odintsova 1999;
Liu, Taube et al. 2005; Jung, Liu et al. 2006). TIMP-1 has also been shown to have both cell
growth promoting and cell growth inhibiting activities in various cell lines, which are
independent from N-terminal domain-mediated inhibition of MMPs (Bertaux, Hornebeck et
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al. 1991; Hayakawa, Yamashita et al. 1992; Chesler, Golde et al. 1995; Taube, Liu et al.
2006). Likewise, there are several conflicting reports in the literature regarding the role of
TIMP-2 in mediating cell growth and apoptosis pathways. In the MCF-7 breast cancer cell
line TIMP-2 had demonstrated cell growth promoting activity, which occurred through
association of the TIMP-2 C-terminal domain with MT1-MMP on the cell surface to activate
the MAPK pathway (section 1.6.2.) (D'Alessio, Ferrari et al. 2008). In contrast, TIMP-2
inhibited cell growth through binding to α3β1 integrin receptors, leading to upregulation of
the cyclin dependent kinase inhibitor p27kip1 in cultured human endothelial cells.
Interestingly, this association also led to increased expression of RECK, and subsequently
decreased cell migration (section 1.6.2.) (Oh, Seo et al. 2004; Seo, Li et al. 2006). The role of
TIMP-2 in regulating apoptosis is also unclear, and varies between different cell types.
Whereas TIMP-2 has been shown to suppress apoptosis in melanoma cells, in human Tlymphocytes TIMP-2 promoted apoptosis (Valente, Fassina et al. 1998; Lim, Guedez et al.
1999).
In contrast to TIMP-1 and -2, TIMP-3 is sequestered in the ECM and consequently,
has limited direct ability to participate in cell surface signaling events (discussed in section
1.6.2.) (Stetler-Stevenson 2008). However, as previously mentioned, TIMP-3 is a good
inhibitor of ADAM family proteases, particularly ADAM-17 (also known as TACE (TNF-α
converting enzyme)). ADAM-17 facilitates the shedding of transforming growth factor-α
(TNF-α) as well as various cell surface receptors including FAS and TNF-related apoptosis
inducing ligand receptor 1 (TRAIL-R1) (Pavloff, Staskus et al. 1992; Black 2002). Thus,
although TIMP-3 has been associated with some cellular signaling pathways, particularly
with changes in apoptosis, this activity is thought to occur indirectly as a result of ADAM
inhibition, rather than as a result of direct signaling activity (Stetler-Stevenson 2008).
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4.1.2. TIMPs in vivo
In vivo, TIMP knockout mouse models display developmental deficiencies,
demonstrating the importance of TIMPs in regulating normal development. In particular,
TIMP-1 and -2 specifically, have been associated with defects in brain and neural
development. TIMP-1 null mice had diminished neuronal development and impaired learning
and memory (Jourquin, Tremblay et al. 2005; Chaillan, Rivera et al. 2006), while TIMP-2
null mice showed decreased neurite outgrowth, delayed neuronal differentiation and
considerable motor dysfunction (Perez-Martinez and Jaworski 2005; Jaworski, Soloway et al.
2006), though the precise mechanisms through which these defects manifested remain
unclear. In contrast, TIMP-3 null mice predominantly showed increased apoptosis in cells of
the mammary glands, and defective alveolar and lung development (Fata, Leco et al. 2001;
Leco, Waterhouse et al. 2001), both of which have been attributed to enhanced MMP activity
(Brew and Nagase 2010). In X. laevis, ectopic expression of TIMP-3 has been associated
with perturbation of head and neural structures (Pickard and Damjanovski 2004), a finding
that I have corroborated using full-length and N-terminal domain TIMP-3 constructs (but not
C-terminal TIMP-3), also indicating that the role of TIMP-3 in development is dependent on
its MMP-inhibitory activities (Chapter 2) (Nieuwesteeg, Walsh et al. 2012).

4.1.3. Experimental approach
Due to the conflicting roles of the TIMP C-terminal domains in different cell lines in
vitro, there is a need to further examine TIMP domain function in vivo to determine whether
TIMP-mediated signaling activities are conserved between whole organisms and cell culture
models. There is also a need to improve our understanding of how the activities of the two
TIMP domains are balanced within the complex ECM proteolytic network in vivo. I have
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previously shown that during development, the X. laevis TIMP-1 and -2 C-terminal domains
can regulate MMP amounts and activity levels independent of N-terminal domain MMPinhibitory activity (Chapters 2 and 3), indicating a unique role for the TIMP C-terminal
domains in regulating the stoichiometry of molecules within the ECM proteolytic network.
TIMPs have been associated with apoptosis, cell proliferation, and migration (RECK)
pathways in vitro, and as these pathways are all important regulators of developmental
events, I wanted to investigate whether the TIMP C-terminal domains also have the ability to
alter these pathways during development. As TIMP-1, -2 and -3 have all been linked to
neural development in other in vivo studies, and my previous research has shown that
overexpression of many of my TIMP constructs disrupted normal head and neural
development (see sections 2.3.4., 2.3.5., and 3.3.3.), in this chapter I have specifically
examined head histological sections of embryos injected with either full-length, N-terminal,
or C-terminal domain TIMP-1, -2 or -3 constructs. Due to the severe nature of the
developmental defects in many of the TIMP injected embryos, it was difficult to identify
specific head structures. Accordingly, anterior sections from embryos at developmental stage
30 (organogenesis) were examined using immunohistochemistry (IHC). Using IHC I assayed
for changes in markers of cell proliferation and apoptosis, as well as for changes in RECK
protein levels. While analysis of changes in anterior expression could be used to confirm the
known important neural and head roles played by TIMPs, a comparison of relative levels of
signaling markers in specific tissues could not be compared between these deformed
embryos. Therefore, I also collected whole embryo protein lysates from injected embryos and
used Western blot analysis to quantify and compare changes in levels of proliferation and
apoptosis markers, as well as in RECK protein levels. The purpose of this research was to
compare the effects of the TIMP C-terminal domain constructs to their respective N-terminal
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domains, and to demonstrate whether the TIMP C-terminal domains have any unique
abilities to alter these signaling pathways in vivo. Specifically, changes in apoptosis were
assayed using active caspase-3 antibody, proliferation via a phosho-histone-3 (PH3)
antibody, and RECK protein levels using a RECK antibody.

4.2 Materials and Methods
4.2.1. Animals
Adult X. laevis were purchased from Xenopus I Inc (Dexter, MI), and fertilized,
reared and housed as described in section 2.2.2.

4.2.2. Generation of TIMP constructs for microinjection
Briefly, PCR was used to produce HA-tagged full-length, N-terminal and C-terminal
domain constructs for TIMP-1, -2 and -3. Details regarding TIMP construct generation can
be found in section 2.2.4. for TIMP-2 and -3, and section 3.2.4. for TIMP-1.

4.2.3. Microinjection of TIMP-1, -2 and -3 mRNA constructs in X. laevis embryos
Fertilized embryos at the 1 cell stage were microinjected with TIMP-1, -2 or -3 fulllength, N-terminal or C-terminal domain mRNA constructs. Microinjections were preformed
as previously described in sections 2.2.5. and 3.2.5. Embryos were monitored until
developmental stage 30 (2 days post-fertilization).

4.2.4. Protein preparations and Western blotting
Protein was extracted from stage 30 embryos injected with the various TIMP
constructs, or uninjected control embryos. Protein extraction, quantification and Western
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blotting were preformed from 10 pooled embryos from 3 independent experiments, as
previously described in section 3.2.7. Primary antibodies used were RECK (H-300) (rabbit
polyclonal, 1:200 dilution; Santa Cruz), p-Histone H3 (ser-10) (rabbit polyclonal, 1:200
dilution; Santa Cruz), anti-active caspase-3 (rabbit polyclonal,1:500 dilution; Abcam), and
anti-β-actin (C4) (mouse monoclonal, 1:1000 dilution; Santa Cruz). Secondary antibodies
used were goat anti-rabbit HRP (1:5000 dilution; Life Technologies) or goat anti-mouse HRP
(1:5000 dilution; Bio-Rad). Western blots were visualized and photographed using Bio-Rad
Quantity One 4.4.0 software. Densitometry was performed using ImageJ software, where
levels of PH3, RECK or caspase-3 were standardized to β-actin, and plotted as mean ± SE
based on 3 independent experiments.

4.2.5. Immunohistochemistry and fluorescence microscopy
Stage 30 embryos injected with TIMP-1, -2 or -3 full-length, N-terminal or Cterminal mRNA constructs, or control (uninjected) embryos were fixed for 2 hr at room
temperature in 3.7% paraformaldehyde in 1X phosphate buffered saline (PBS). Fixed
embryos were dehydrated in 70% ethanol and sectioned at the Molecular Pathology Core
Facility in Robarts Research Institute (London, ON). Embryos were embedded in paraffin,
sectioned at a thickness of 6 µm, and mounted on glass slides. Slides were washed in xylene
for 15 min to deparaffinize the sections, and then gradually rehydrated through a series of 5
min washes in 100% ethanol, 90% ethanol + 10% PBST (1x phosphate-buffered saline +
0.1% Triton-X (Sigma)), and 80% ethanol + 20% PBST, followed by two 5 min washes in
100% PBST. Sections were blocked with 10% goat serum in 1X PBST for 45 min at room
temperature. Note: For sections labeled with RECK antibody, 1X PBS was used in place of
1X PBST for all washes described above. Immunostaining was performed by incubating
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sections with primary antibodies against RECK (H-300) (rabbit polyclonal; Santa Cruz), pHistone H3 (ser-10) (rabbit polyclonal; Santa Cruz), or anti-active caspase-3 (rabbit
polyclonal; Abcam). All primary antibodies were used at a 1:50 dilution and incubated
overnight at 4 °C. Caspase-3 and PH3 antibodies were diluted in 2% BSA in PBST, and
RECK antibody was diluted in 2% BSA in PBS. Slides were washed 3 times for 5 min in
PBST (PBS for RECK labeled sections), and incubated for with secondary antibody at a
1:200 dilution for 2 hr at room temperature (Alexa Fluor® 488 Goat Anti-Rabbit IgG; Life
Technologies). Secondary antibodies were diluted in 2% BSA in PBST for caspase-3 and
PH3 labeled sections, and in 2% BSA in PBS for RECK labeled sections. Sections were
washed 3 times for 5 min in PBST (PBS for RECK labeled sections), followed by one 5 min
wash in double-distilled H2O. All sections were mounted and counterstained with ProLong®
Gold

antifade

reagent

containing

4',

6-diamidino-2-phenylindole

(DAPI)

(Life

Technologies). Anterior head portions of embryos in a 200X field of view were visualized
and photographed using a Leica DMI600 B microscope and Leica MM AF 1.4.0 software.
ImageJ software was used to measure PH3, caspase-3 or RECK signal relative to DAPI
(indicative of total number of cells) in anterior head sections of injected embryos all the same
magnification (200X). Immunohistochemistry and quantification of fluorescence are
representative measurements based on 1 image, with 4 consistent technical repeats for each
embryo imaged. Results were consistent and observed in no less than 2 embryos.

4.2.6. Statistical Analysis
All statistical analysis was performed using the IBM SPSS Statistic 19 program.
Results were presented as mean ± SE. Western blot data were log transformed (Log10) to
achieve normal distribution. Statistical significance was determined using One Way ANOVA
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variance analysis followed Dunnett’s multiple comparisons test. Differences were considered
statistically significant when p < 0.05.

4.3 Results
4.3.1. Overexpression of full-length, N-terminal and C-terminal TIMP constructs did not
alter PH3 levels in X. laevis embryo sections or protein lysates
PH3 was used as an indicator of cell proliferation in order to characterize the roles of
the TIMP-1, -2 and -3 N- and C-terminal domains in regulating this pathway during
development. Immunostaining of anterior head sections from stage 30 embryos showed that
overexpression of full-length, N-terminal or C-terminal domain TIMP-1 resulted in relatively
equal levels of PH3 compared to control embryos (Fig. 4.1 A). Western blot analysis from
whole embryo protein lysates confirmed this trend, as changes in PH3 levels were not
significantly different from control embryos following injection of any of the TIMP-1
constructs (Fig. 4.1 B). Similarly, overexpression of TIMP-2 full-length, N-terminal or Cterminal domain constructs did not alter levels of PH3 relative to control embryos. Although
the T2N construct resulted in slightly decreased levels of PH3 as examined by IHC (Fig. 4.2
A), this decrease was statistically insignificant when quantified via Western blot (Fig. 4.2. B,
p > 0.05). Additionally, none of the TIMP-3 constructs altered PH3 levels compared to
control (uninjected) embryos (Fig. 4.3 A and B), suggesting that TIMPs may not significantly
impact proliferation in X. laevis embryos.
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Figure 4.1. TIMP-1 N- or C-terminal domains did not alter PH3 levels in X. laevis
embryos. Embryos were injected at the 1 cell stage with 4 ng of either TIMP-1 full-length
(T1FL), N-terminal domain (T1N) or C-terminal domain (T1C) mRNA constructs. (A)
Anterior sections from stage 30 embryos (200X magnification) were analyzed for changes in
PH3 (green) as an indicator of cell proliferation. The level of PH3 relative to DAPI (blue)
fluorescence levels was measured for each section (ratio is Y-axis) and depicted graphically
(black bars). (B) Western blot analysis was performed to measure changes in PH3 levels
from whole embryo protein lysates. PH3 levels were measured relative to β-actin. Results are
displayed as mean ± SE from 3 independent experiments. No significant changes in PH3
levels relative to control uninjected (CONT) embryos were observed following
overexpression of any TIMP-1 constructs, as analyzed by one-way ANOVA and Dunnett’s
multiple comparisons test (p > 0.05).
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Figure 4.2. TIMP-2 N- or C-terminal domains did not alter PH3 levels in X. laevis
embryos. Embryos were injected at the 1 cell stage with 4 ng of either TIMP-2 full-length
(T2FL), N-terminal domain (T2N) or C-terminal domain (T2C) mRNA constructs. (A)
Anterior sections from stage 30 embryos (200X magnification) were analyzed for changes in
PH3 (green) as an indicator of cell proliferation. The level of PH3 relative to DAPI (blue)
fluorescence levels was measured for each section (ratio is Y-axis) and depicted graphically
(black bars). (B) Western blot analysis measured changes in PH3 levels from whole embryo
protein lysates. PH3 levels were measured relative to β-actin. Results are displayed as mean
± SE from 3 independent experiments. No significant changes in PH3 levels relative to
control uninjected (CONT) embryos were observed following overexpression of any TIMP-2
constructs, as analyzed by one-way ANOVA and Dunnett’s multiple comparisons test (p >
0.05).
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Figure 4.3. TIMP-3 N- or C-terminal domains did not alter PH3 levels in X. laevis
embryos. Embryos were injected at the 1 cell stage with 4 ng of either TIMP-3 full-length
(T3FL), N-terminal domain (T3N) or C-terminal domain (T3C) mRNA constructs. (A)
Anterior sections from stage 30 embryos (200X magnification) were analyzed for changes in
PH3 (green) as an indicator of cell proliferation. The level of PH3 relative to DAPI (blue)
fluorescence levels was measured for each section (ratio is Y-axis) and depicted graphically
(black bars). (B) Western blot analysis measured changes in PH3 levels from whole embryo
protein lysates. PH3 levels were measured relative to β-actin. Results are displayed as mean
± SE form 3 independent experiments. No significant changes in PH3 relative to control
uninjected (CONT) embryos were observed following overexpression of any TIMP-3
constructs, as analyzed by one-way ANOVA and Dunnett’s multiple comparisons test (p >
0.05).

Expression relative to actin

!
127

!

128

4.3.2. Overexpression of full-length and C-terminal TIMP-1 constructs increased active
caspase-3 levels in X. laevis embryos
Active caspase-3 was used as an indicator of apoptosis to measure differences in the
abilities of TIMP-1, -2 or -3 full-length, N- or C-terminal domain constructs to alter this
pathway during development. Immunohistochemical examination of anterior head sections
from stage 30 embryos demonstrated increased caspase-3 levels following overexpression of
T1FL and T1C constructs (Fig. 4.4 A). These increases were confirmed as significant
through Western blot analysis from whole embryo protein lysates at the same developmental
stage (Fig. 4.4 B, p < 0.05). In contrast, quantification of caspase-3 levels via Western blot
analysis demonstrated that none of the TIMP-2 constructs significantly altered caspase-3
levels relative to control embryos (Fig. 4.5 B); however, the trend was toward the increase
following overexpression of T2FL and T2C constructs in both IHC and Western blot
analyses (Fig. 4.5 A and B). Similarly, overexpression of TIMP-3 constructs did not result in
significantly altered caspase-3 levels compared to control embryos (Fig. 4.6 A and B).
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Figure 4.4. Overexpression of TIMP-1 full-length and C-terminal domain constructs
increased active caspase-3 levels in X. laevis embryos. Embryos were injected at the 1 cell
stage with 4 ng of either TIMP-1 full-length (T1FL), N-terminal domain (T1N) or C-terminal
domain (T1C) mRNA constructs. (A) Anterior sections from stage 30 embryos (200X
magnification) were analyzed for changes in active caspase-3 (green) as an indicator of cell
death. The level of caspase-3 relative to DAPI (blue) fluorescence levels was measured for
each section (ratio is Y-axis) and depicted graphically (black bars). (B) Western blot analysis
measured changes in caspase-3 levels from whole embryo protein lysates. Caspase-3 levels
were measured relative to β-actin. Results are displayed as mean ± SE from 3 independent
experiments. TIFL and T1C constructs significantly increased caspase-3 levels relative to
control uninjected (CONT) embryos, as analyzed by one-way ANOVA and Dunnett’s
multiple comparisons test *(p < 0.05).
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!
130

!

131

Figure 4.5. Overexpression of TIMP-2 constructs did not alter active caspase-3 levels in
X. laevis embryos. Embryos were injected at the 1 cell stage with 4 ng of either TIMP-2 fulllength (T2FL), N-terminal domain (T2N) or C-terminal domain (T2C) mRNA constructs.
(A) Anterior sections from stage 30 embryos (200X magnification) were analyzed for
changes in active caspase-3 (green) as an indicator of cell death. The level of caspase-3
relative to DAPI (blue) fluorescence levels was measured for each section (ratio is Y-axis)
and depicted graphically (black bars). (B) Western blot analysis measured changes in
caspase-3 levels from whole embryo protein lysates. Caspase-3 levels were measured relative
to β-actin. Results are displayed as mean ± SE from 3 independent experiments. TIMP-2
constructs did not significantly alter caspase-3 levels relative to control uninjected (CONT)
embryos, as analyzed by one-way ANOVA and Dunnett’s multiple comparisons test (p >
0.05).

Expression relative to actin

!
132

!

133

Figure 4.6. Overexpression of TIMP-3 constructs did not alter active caspase-3 levels in
X. laevis embryos. Embryos were injected at the 1 cell stage with 4 ng of either TIMP-3 fulllength (T3FL), N-terminal domain (T3N) or C-terminal domain (T3C) mRNA constructs.
(A) Anterior sections from stage 30 embryos (200X magnification) were analyzed for
changes in active caspase-3 (green) as an indicator of cell death. The level of caspase-3
relative to DAPI (blue) fluorescence levels was measured for each section (ratio is Y-axis)
and depicted graphically (black bars). (B) Western blot analysis measured changes in
caspase-3 levels from whole embryo protein lysates. Caspase-3 levels were measured relative
to β-actin. Results are displayed as mean ± SE from 3 independent experiments. TIMP-3
constructs did not significantly alter caspase-3 levels relative to control uninjected (CONT)
embryos, as analyzed by one-way ANOVA and Dunnett’s multiple comparisons test (p >
0.05).

Expression relative to actin
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4.3.3. Overexpression TIMP constructs altered RECK levels in X. laevis embryos
To examine whether any of the TIMP domains had the ability to regulate RECK
protein levels during development, changes in RECK levels were analyzed following
overexpression of full-length, N-, and C-terminal domain constructs in X. laevis embryos. All
changes were confirmed at both the IHC and Western blot level. Western blot analysis from
stage 30 embryos showed that RECK expression was significantly increased following
overexpression of TIFL and T1C constructs (Fig. 4.7 B, p < 0.05). In contrast, whereas
overexpression of full-length and N-terminal domain TIMP-2 did not significantly alter
RECK levels, the T2C construct resulted in decreased levels of RECK relative to control
embryos that were detectable by IHC (Fig. 4.8 A) and confirmed as significant by Western
blot (Fig. 4.8 B, p < 0.05). Additionally, while the TIMP-3 full-length and C-terminal domain
constructs did not result in changes in RECK compared to controls, the T3N construct
significantly decreased RECK levels compared to controls. Again, this decrease was detected
by both IHC and Western blot analysis (Fig. 4.9 A and B, p < 0.05).
!
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Figure 4.7. Overexpression of TIMP-1 full-length and C-terminal domain constructs
increased RECK in X. laevis embryos. Embryos were injected at the 1 cell stage with 4 ng
of either TIMP-1 full-length (T1FL), N-terminal domain (T1N) or C-terminal domain (T1C)
mRNA constructs. (A) Anterior sections from stage 30 embryos (200X magnification) were
analyzed for changes in RECK expression (green). The level of RECK relative to DAPI
(blue) fluorescence levels was measured for each section (ratio is Y-axis) and depicted
graphically (black bars). (B) Western blot analysis measured changes in RECK levels from
whole embryo protein lysates. RECK levels were measured relative to β-actin. Results are
displayed as mean ± SE from 3 independent experiments. TIFL and T1C constructs
significantly increased RECK relative to control uninjected (CONT) embryos, as analyzed by
one-way ANOVA and Dunnett’s multiple comparisons test *(p < 0.05).
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Figure 4.8. Overexpression of the TIMP-2 C-terminal domain construct decreased
RECK in X. laevis embryos. Embryos were injected at the 1 cell stage with 4 ng of either
TIMP-2 full-length (T2FL), N-terminal domain (T2N) or C-terminal domain (T2C) mRNA
constructs. (A) Anterior sections from stage 30 embryos (200X magnification) were analyzed
for changes in RECK expression (green). The level of RECK relative to DAPI (blue)
fluorescence levels was measured for each section (ratio is Y-axis) and depicted graphically
(black bars). (B) Western blot analysis measured changes in RECK levels from whole
embryo protein lysates. RECK levels were measured relative to β-actin. Results are displayed
as mean ± SE from 3 independent experiments. The T2C construct significantly decreased
RECK levels relative to control uninjected (CONT) embryos, as analyzed by one-way
ANOVA and Dunnett’s multiple comparisons test *(p < 0.05).

Expression relative to actin
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Figure 4.9. Overexpression of the TIMP-3 N-terminal domain construct decreased
RECK in X. laevis embryos. Embryos were injected at the 1 cell stage with 4 ng of either
TIMP-3 full-length (T3FL), N-terminal domain (T3N) or C-terminal domain (T3C) mRNA
constructs. (A) Anterior sections from stage 30 embryos (200X magnification) were analyzed
for changes in RECK expression (green). The level of RECK relative to DAPI (blue)
fluorescence levels was measured for each section (ratio is Y-axis) and depicted graphically
(black bars). (B) Western blot analysis measured changes in RECK levels from whole
embryo protein lysates. RECK levels were measured relative to β-actin. Results are displayed
as mean ± SE from 3 independent experiments. The T3N construct significantly decreased
RECK levels relative to control uninjected (CONT) embryos, as analyzed by one-way
ANOVA and Dunnett’s multiple comparisons test *(p < 0.05).
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4.4 Discussion
I have previously shown that overexpression of all TIMP constructs, with the
exception of the TIMP-3 C-terminal domain, resulted in severe developmental defects,
including head, neural tube and axis defects, and that the TIMP-1 and -2 C-terminal domains
altered MMP levels independent of MMP inhibition (see Chapter 2 and 3). As the TIMP-1
and -2 C-terminal domains have been shown to regulate cell proliferation and apoptosis
pathways in vitro, I wanted to investigate whether TIMPs may also contribute to cell
signaling in vivo. In order to understand whether the TIMP C-terminal domains also have
unique abilities to contribute to regulation of signaling pathways during development, I
overexpressed TIMP-1, -2 or -3 full-length, N-terminal and C-terminal domain constructs in
X. laevis embryos, and examined changes in levels of PH3 as an indicator of cell
proliferation and active caspase-3 as a indicator of apoptosis. Additionally, I examined
changes in RECK levels, as the TIMP-2 C-terminal domain has previously been shown to
increase RECK expression in cultured human endothelial cells (Oh, Seo et al. 2004). PH3,
caspase-3 and RECK were examined using IHC and Western blot. Due to the nature of the
severe developmental defects resulting from overexpression of TIMP constructs,
developmental landmarks were difficult to identify, and changes in localization could not be
observed by IHC. Accordingly, the levels of PH3, caspase-3 and RECK were examined in
anterior head sections from injected and control embryos and measured relative to DAPI.
Western blot analysis using whole embryo protein lysates was used to corroborate trends
observed in IHC and also quantify changes in the levels PH3, caspase-3 and RECK in stage
30 embryos.
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4.4.1. Ectopic expression of TIMP constructs did not alter cell proliferation in X. laevis
embryos
Overexpression of TIMP-1, -2 or -3 full-length, N-terminal or C-terminal domain
constructs did not result in significantly altered cell proliferation in X. laevis embryos, as
indicated by changes in the levels of PH3. Although modest decreases in the levels of PH3
relative to DAPI were observed in some embryo sections using IHC, these decreases were
deemed insignificant by Western blot analysis from whole embryo protein lysates (Fig. 4.1,
4.2 and 4.3). Interestingly, even the C-terminal domain constructs of TIMP-1 and -2 did not
significantly alter proliferation relative to control embryos, indicating that there may be no
direct or indirect roles for TIMPs in regulating this pathway during X. laevis development.
Both the TIMP-1 and -2 C-terminal domains have been demonstrated in various cancer and
fibroblast cell lines to either promote or inhibit cell proliferation (reviewed in StetlerStevenson 2008), however, these experiments were performed using homogenous
populations of differentiated cells. Although TIMPs may impact cell proliferation pathways
through C-terminal domain-mediated cell signaling events in differentiated cell lines in
culture, this mechanism may not be maintained in undifferentiated cells in embryos.
Pluripotent or multipotent cells in the embryo are subject to distinct regulatory parameters,
where TIMPs may not have the ability to alter proliferation. Although it is possible that small
populations of cells in the embryo may be sensitive to TIMP-mediated changes in
proliferation, these changes were not reflected in the whole embryo, at least as demonstrated
by PH3 assays. A more careful analysis of localized changes in proliferation must be carried
out to conclusively rule out a role for TIMPs regulating proliferation pathways during
development.
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4.4.2. The TIMP-1 C-terminal domain increased active caspase-3 in X. laevis embryos
To investigate whether any of the X. laevis TIMPs had the ability to alter cell death
during development (particulary through their C-terminal domains), I examined changes in
active caspase-3 as an indicator of apoptosis, following overexpression of each of my TIMP
constructs. The TIMP-1 full-length and C-terminal domain constructs significantly increased
caspase-3 levels relative to control embryos (Fig. 4.4.). As the C-terminal domain construct
has no MMP-inhibitory activity (see section 3.3.7.), this data suggests that changes in
apoptosis are mediated by a C-terminal domain-specific mechanism, presumably cell
signaling. While the TIMP-1 C-terminal domain has been linked to changes in apoptosis in
both human lymphoma and mammary epithelia cell lines, these in vitro studies are associated
with suppression of apoptosis, rather than the increase in apoptosis observed here (Guedez,
Stetler-Stevenson et al. 1998; Berditchevski and Odintsova 1999; Li, Fridman et al. 1999;
Guedez, Mansoor et al. 2001; Jung, Liu et al. 2006). Although the importance of the TIMP-1
C-terminal domain in regulating caspase-3 levels seems to be maintained in X. laevis, the
effects of this protein may be different during development. This may be due to the fact that
the embryo consists of a heterogeneous population of differentiating cells, where cell fate
decisions are mediated in a highly complex manner, in contrast to the homogeneous
populations of differentiated cells used in in vitro studies. Nevertheless, the role of TIMP-1
in regulating amount of active caspase-3 during X. laevis development seems to be specific to
the TIMP-1 C-terminal domain, as only the T1C and T1FL constructs (which contain a
functional C-terminus) increased apoptosis. Furthermore, none of the TIMP-2 or -3
constructs resulted in significantly altered levels of caspase-3 relative to control embryos,
demonstrating that this effect is unique to TIMP-1.
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Though a similar trend was observed following overexpression of T2FL and T2C

constructs (Fig. 4.5), the resultant increases in caspase-3 were not significant compared to
controls, indicating the TIMP-2 C-terminal domain may not play an important role in
regulating this pathway during development. With only two conflicting reports in the
literature regarding the effect of TIMP-2 on apoptosis (Valente, Fassina et al. 1998; Lim,
Guedez et al. 1999), it is possible that TIMP-2 is simply not an important regulatory factor
for this pathway. Additionally, while overexpression of the TIMP-3 constructs did not
significantly alter caspase-3 levels relative to control embryos, modest increases in levels of
caspase-3 were detected following overexpression of T3FL and T3N (but not T3C)
constructs by IHC analysis, and these trends were mirrored by Western blot analysis (Fig.
4.6). This is consistent with reports in the literature, which indicate that TIMP-3 may
indirectly alter apoptosis through regulation of MMP and ADAM activity (Stetler-Stevenson
2008). The TIMP-3 C-domain, which has no inherent MMP-inhibitory (or signaling) activity,
did not follow this trend.

4.4.3. The TIMP-1 and -2 C-terminal domains had opposing effects on RECK protein
levels in X. laevis embryos
RECK is a potent cell surface inhibitor of MMPs, thus, alterations in RECK
expression may have considerable effects on cell migration during embryogenesis. As TIMP2 has previously been demonstrated to increase RECK expression in vitro (Oh, Seo et al.
2004), here I investigated whether the X. laevis TIMPs or their individual domains may
contribute to regulation of RECK expression in vivo, during development. Intriguingly, the
TIMP-1 full-length and C-terminal domain constructs resulted in significantly increased
levels of RECK protein when quantified using Western blot analysis (Fig. 4.7 B). The T1N
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construct, which only functions in inhibition of MMP activity, did not result in changes in
RECK expression relative to control embryos. Thus, this data suggests that the observed
increases in RECK following overexpression of T1FL and T1C constructs are due to a Cterminal domain specific mechanism. No previous reports have linked the TIMP-1 Cterminal domain to a particular cell signaling pathway involved in the regulation of RECK
expression; however, to date there has been limited research investigating TIMP-1-mediated
regulation of RECK and other components of the ECM proteolytic network.
Following overexpression of TIMP-2 full-length, N-, and C-terminal domain
constructs, I found that only the T2C construct significantly decreased RECK expression
relative to controls, whereas the T2FL and T2N constructs did not (Fig. 4.8). This finding is
in contrast to the report by Oh et al. (2004), which showed that the TIMP-2 C-terminal
domain increased RECK expression through binding to α3β1 integrin receptors on the
surface of human microvascular endothelial cells. As the effect of TIMP-2 on regulation of
RECK expression has currently only been examined using cultured human endothelial cells,
it is possible that TIMP-2 may have varying effects on RECK expression, or may alter RECK
expression through different pathways, depending on the requirements of different tissues
and organisms. My research, however, demonstrated that TIMP-2 has the ability to alter
RECK through its C-terminal domain, independent of MMP inhibition, during X. laevis
development.
In contrast, overexpression of full-length and C-terminal domain TIMP-3 did not
alter RECK relative to control embryos, indicating that the TIMP-3 C-terminal domain does
not participate in signaling events that regulate RECK expression in X. laevis embryos. The
T3N construct, however, did result in significantly decreased RECK levels relative to control
embryos when analyzed by Western blot. As the TIMP N-terminal domains are involved in
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MMP inhibition, and have not been associated with direct signaling activity, it is unlikely
that the T3N construct decreased RECK expression through a direct signaling mechanism.
Rather, the explanation may be simply due to the stoichiometry of MMP inhibitors within the
ECM. Under normal conditions, full-length TIMP-3 is sequestered in the ECM away from
the cell surface, a function that is mediated by its C-terminal domain (Yu, Yu et al. 2000),
Thus, whereas the T3FL and T3C constructs may remain bound to the ECM, this ability
would be impaired with the T3N construct. The T3N construct is free to act pericellularly,
and therefore, may result in feedback to the cell to downregulate expression of other MMP
inhibitors, like RECK.

4.4.4. Concluding remarks
This research is the first detailed comparison of the unique functions of the TIMP Nand C-terminal domains in vivo. Although a more thorough analysis is needed to identify
binding partners and receptors for the TIMP C-terminal domains in vivo, I have shown for
the first time that the TIMP-1 and -2 C-terminal domains have the ability to influence cell
signaling pathways in X. laevis embryos. This research indicates that TIMPs may be
important not only for mediating MMP activity during development, but also for regulating
cell signaling pathways that influence apoptosis and cell migration, through RECK.
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CHAPTER 5
GENERAL DISCUSSION AND CONCLUSIONS
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5.1 General Overview
5.1.1. Context and significance of this research
In recent years, the complexity underlying ECM dynamics has become apparent, as
research has demonstrated the importance of maintaining the appropriate balance between
ECM proteases and inhibitors in both development and disease. Not only is the balance
between MMPs and TIMPs important for facilitating cell migration during development and
metastasis (Liotta, Steeg et al. 1991; Blelloch and Kimble 1999), but TIMP-mediated
inhibition of MMPs can also indirectly influence cell behavior by altering the availability and
activity of secreted signaling molecules within the ECM (Brew and Nagase 2010). It has also
become evident that TIMPs themselves may be important determinants of cell fate, as in
vitro studies have shown that TIMP initiated cell signaling cascades can have significant
consequences on apoptosis, cell migration, and cell proliferation pathways (Stetler-Stevenson
2008; Brew and Nagase 2010). Due to the multifaceted roles of both MMPs and TIMPs,
analysis of the functions of, and interactions between, ECM molecules has become
exceedingly complex, particularly in vivo, where TIMP and MMP activities may be altered
by the presence and relative abundance of different ECM components. To my knowledge,
there have been no previous studies that have examined and compared the unique roles of the
different TIMP N-terminal MMP-inhibitory and C-terminal cell-signaling domains in vivo.
The research presented in this thesis is the first comprehensive comparison of the individual
TIMP domains in vivo, as well as the first examination of TIMP domain functions as they
pertain to development.
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5.1.2. Research summary and general conclusions
The overall goal of this research was to investigate in isolation the N- and C-terminal
domains of all three X. laevis TIMPs during development, and to compare the effects of
overexpression of the individual domains between the different TIMPs, as well as with their
full-length counterparts. By using a series of domain-specific overexpression experiments
and assays for: 1) gross morphological changes in development, 2) changes in the mRNA
levels of ECM genes, 3) changes in the levels of active ECM proteases, and 4) changes in
indicators of cell signaling pathways, I have performed a comprehensive comparison of
TIMP domain function during X. laevis development. In general, my hypothesis was that
overexpression of the TIMP N-terminal domains would have more similar effects on
development, as inhibition of MMPs is a function common to all TIMPs; whereas,
overexpression of the TIMP C-terminal domains would have varying effects on development,
depending on their distinct abilities to participate in cell surface signaling events. Indeed, I
have demonstrated that the TIMP-1 and -2 C-terminal domains have unique abilities to
contribute to development that are mirrored following overexpression of the full-length
construct. This research used C-terminal domain TIMP constructs to demonstrate in vivo the
MMP-independent effects of TIMPs (that can be attributed to direct cell signaling functions)
vs. the changes in development that arise due to TIMP inhibition of target proteases (through
their N-terminal domains).

5.2 Contributions to the Current Knowledge of ECM Dynamics During Development
5.2.1. Identification and characterization of X. laevis TIMPs
At the time this research was started, only X. laevis TIMP-2 and -3 genes had been
identified. One of the firsts tasks I was faced with when beginning this project was to identify
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and clone TIMP-1 and/or TIMP-4. As mentioned in section 1.3, while four TIMPs are present
in mammals, many vertebrates do not express orthologs of all four TIMPs (Murphy 2011).
Using database searches, I identified an unannotated X. laevis clone (AAI41767.1), which
was highly homologous with other known TIMP-1 sequences at the amino acid level.
Presently, there is no TIMP-4 in X. laevis based on available sequence data. It is possible that
a TIMP-4 sequence may still be discovered as the sequencing of the X. laevis genome is still
underway. However, Xenopus tropicalis, a closely related species to X. laevis, has been fully
sequenced. Although a TIMP-1 ortholog has been identified, no TIMP-4 sequence has been
discovered in X. tropicalis. In mammals, TIMP-4 has the most selective and restricted pattern
of localization, with expression primarily in brain and heart (Baker, Edwards et al. 2002;
Nuttall, Sampieri et al. 2004). Structurally, human TIMP-4 is most similar to TIMP-2
(Melendez-Zajgla, Del Pozo et al. 2008), though studies suggest that the signaling
capabilities of TIMP-4 are most similar to those of TIMP-1 (Stetler-Stevenson 2008). It is
possible that the functions of TIMP-4 may be redundant with those of the other TIMPs, thus,
some lower vertebrates such as frog may not contain TIMP-4 along with TIMP-1 or -2.
Indeed, the fish Takifugu rubripes expresses TIMP-2, -3 and -4 but not TIMP-1, whereas
insects such as Drosophila melanogaster express only one TIMP (Brew, Dinakarpandian et
al. 2000; Tsukamoto, Yokoyama et al. 2006; Tsukamoto, Yokoyama et al. 2007; Brew and
Nagase 2010).
Amino acid sequence comparison of the three X. laevis TIMPs compared with those
from other known full-length vertebrate and invertebrate species revealed that the N-terminal
domains of TIMP-1 and -2 were more highly conserved than their C-terminal domains. This
was expected, as the N-terminal domains are involved in the similar function of MMP
inhibition, whereas the C-terminal domains of TIMP-1 and -2 have variable roles in cell
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signaling that depend on cell and tissue type (Stetler-Stevenson 2008). The signaling
functions of the C-terminal domains likely also vary between species; however, to date TIMP
C-terminal domain function has only been examined in human, mouse and rat cell lines.
Phylogenetic analysis of TIMP-1, -2 and -3 N- and C-terminal domains with those of other
known species showed that for TIMP-1 and -3, the N- and C-terminal domains diverged
under different selective pressures, whereas for TIMP-2 the two domains evolved in a
concomitant manner. This study, however, was limited by the number of available annotated
TIMP sequences, particularly from non-mammalian and invertebrate species. A broader
study with more diverse species, as well as additional analysis of TIMP receptors is needed
to truly determine if TIMP C-terminal domains evolved in parallel with changes in specific
receptors and/or signaling pathways.

5.2.2. TIMP C-terminal domains contribute to regulation of development in an MMPindependent manner
TIMPs have long been acknowledged for their roles in MMP inhibition that are
needed for regulation of developmental events involving cell migration. With the emerging
signaling properties of TIMPs in cell migration, proliferation and apoptosis pathways, it was
important to re-examine TIMP function in vivo, as these cell signaling pathways are not only
important in regulation of cancer progression, but also in the regulation of development. The
stoichiometry between MMPs, TIMPs, secreted signaling molecules, and cell surface
receptors are important determinants of TIMP function. By disrupting this stoichiometry
through overexpression of my TIMP constructs in early stage embryos, I have revealed for
the first time in vivo that the TIMP C-terminal domains can contribute to development using
an MMP-independent mechanism.
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Specifically, I have shown that overexpression of the TIMP-1 and -2 C-terminal

domains led to distinct developmental defects and large amounts of embryonic death. These
developmental defects were linked to changes in MMP expression and activity levels, as well
as to specific changes in signaling markers that were also observed following overexpression
of the full-length constructs, but not with the N-terminal domain constructs. As the TIMP-1
and -2 C-terminal domains alone cannot inhibit MMP activity, these results suggest that the
observed development defects occurred through a signaling mechanism. In contrast, the
TIMP-3 C-terminal domain did not disrupt development, or alter any signaling markers
relative to control embryos. This was consistent with my original hypothesis, which stated
that the TIMP-3 C-terminal domain would not alter development on its own (only as part of
the full-length molecule), and was also consistent with evidence from previous in vitro
experiments which reported that TIMP-3 is sequestered in the ECM through its C-terminal
domain, and therefore, does not participate in pericellular signaling events (Langton, Barker
et al. 1998; Yu, Yu et al. 2000; Stetler-Stevenson 2008).
When comparing data in Chapter 2 (TIMP-2 and -3) and Chapter 3 (TIMP-1), one
noticeable result was the ability of both the TIMP-1 and -2 C-terminal domains to alter
MMP-2 and -9 expression at both the mRNA and protein levels. The full-length and Nterminal domains also had varying abilities to alter MMP expression and activity, which may
have occurred as an indirect result of MMP inhibition or due to a regulatory feedback
mechanism within the ECM proteolytic network. However, the fact that the C-terminal
domains also altered MMP expression and activity levels is suggestive of a unique feedback
mechanism, whereby the cell can alter relative levels of ECM proteins in direct response to
TIMP signaling. Surprisingly, TIMP-1 and -2 differed in their abilities to regulate active
MMP-9 protein. TIMP-2 resulted in increased levels of active MMP-9 relative to control
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embryos, whereas TIMP-1 decreased active MMP-9 relative to controls, and this decrease
was most pronounced following overexpression of the C-terminal domain. Though the
precise mechanisms through which the TIMP-1 and -2 C-domains may regulate MMP-9
remain unknown, previous studies have also indicated that a special relationship may exist
between TIMP-1 and pro-MMP-9 (discussed in section 1.5.2.). TIMP-1 and pro-MMP-9
have been demonstrated to complex together in the ECM, a function that is mediated by the
C-terminal domain of TIMP-1 rather than the N-terminal MMP-inhibitory domain
(Goldberg, Strongin et al. 1992; Itoh and Nagase 1995). More recently, in vitro experiments
using human cell lines have shown that TIMP-1 and pro-MMP-9 co-localize within the cell
and are secreted together. This complex has been suggested to be involved in regulation of
MMP-9 activity and stabilization of the pro-enzyme, and may be found in close proximity to
the cell surface (Itoh and Nagase 1995; Roderfeld, Graf et al. 2007). My research suggests
that TIMP-1 may associate with pro-MMP-9 in vivo to regulate MMP-9 activity during
development.
Another intriguing aspect of this study was the ability of the TIMP-1 and -2 (but not
TIMP-3) C-terminal domains to alter specific cell signaling markers in X. laevis embryos. In
chapter 4, I demonstrated that both the TIMP-1 and -2 C-terminal domains altered RECK
protein levels relative to controls, and that these trends were mirrored with overexpression of
the full-length but not N-terminal domain constructs. Again, TIMP-1 and -2 had differing
effects on RECK expression, suggesting that these two TIMPs may regulate expression and
activity within the ECM proteolytic network through different mechanisms (Fig. 5.1).
Although the decrease in RECK protein observed following overexpression of the T2C
construct was in contrast to current literature, which reported an increase in RECK in human
endothelial cell lines (Oh, Seo et al. 2004), this has not been recapitulated in any other cell
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lines or model organisms to date, and could likely vary between species (discussed in detail
in section 4.4.3.). The decrease in RECK protein observed in Western blot and IHC studies
in chapter 4, however, was in agreement with the slight decrease (2-fold decrease relative to
control embryos) in RECK mRNA observed in chapter 2, which provides further support for
the idea that the TIMP-2 C-terminal domain can alter RECK expression through an MMPindependent mechanism. In opposition, the TIMP-1 C-terminal domain resulted in increased
RECK protein (Fig. 5.1). Although a direct signaling mechanism for TIMP-1 mediated
regulation of RECK has not previously been reported, TIMP-1 is unique with respect to the
other TIMPs as in vitro experiments have shown that TIMP-1 can translocate into the nucleus
(Ritter, Garfield et al. 1999). While the nuclear functions of TIMP-1 remain unknown, to my
knowledge, nuclear localization has never been demonstrated for any of the other TIMPs. In
addition, several studies have reported that increased RECK is associated with decreases
MMP-9 mRNA levels as well as secretion of MMP-9 protein (Takahashi, Sheng et al. 1998;
Chang, Hung et al. 2008; Takagi, Simizu et al. 2009). This is in agreement with my data, as I
have shown that while RECK protein is elevated, MMP-9 mRNA and protein are
downregulated at the same developmental stage. These trends are most pronounced following
overexpression of the TIMP-1 C-terminal domain. Taken together, these studies highlight the
complexity of the ECM proteolytic network in vivo, and indicate that TIMP-1 may be an
important regulator of this network during development, and may have important regulatory
functions that have yet to be discovered.
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Fig. 5.1. Model of TIMP signaling during X. laevis development. TIMP-1 binds unknown
receptors through its C-terminal domain to increase active caspase-3 levels and/or RECK
protein levels. TIMP-2 binds to unknown receptors through its C-terminal domain to
decrease RECK protein levels. TIMP-3 remains sequestered in the ECM and has no
independent signaling mechanism during X. laevis development. TIMP C-terminal domain
signaling ability is dependent on relative levels of MMPs and other binding partners in the
ECM, which sequester TIMPs away from the cell surface.
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In addition, the TIMP-1 full-length and C-terminal domains were demonstrated to

significantly increase caspase-3 activity in X. laevis embryos, and this association was not
demonstrated with the TIMP-1 N-terminal domains or with any of the other TIMP constructs
(Fig. 5.1). Caspase-3 was used as an indicator of apoptosis, as active caspase-3 is normally
considered an important effector in apoptotic pathways. My results were in contrast to reports
in the literature, which have demonstrated using several different cell lines that TIMP-1
suppressed rather than promoted apoptosis (Guedez, Stetler-Stevenson et al. 1998;
Berditchevski and Odintsova 1999; Li, Fridman et al. 1999; Guedez, Mansoor et al. 2001;
Jung, Liu et al. 2006). Remarkably, however, a recent study using hematopoietic cells in
culture has reported that TIMP-1 can indeed lead to increased activation of caspase-3, and
that this activation is not associated with increased apoptotic cell death (Dasse, Bridoux et al.
2007). Instead, in this model, increased activation of caspase-3 resulted in cell differentiation
through activation of MEK1, MEK6, and p38α (Dasse, Bridoux et al. 2007). It remains
unclear whether the increase in caspase-3 activation that I observed in association with
overexpression of the TIMP-1 C-terminal domain is indicative of enhanced apoptosis or cell
differentiation. While further studies are needed to investigate additional markers of both
pathways, my research has emphasized that the C-terminal domain, particularly of TIMP-1,
may potentially play intricate roles in the regulation of development.

5.3 Limitations of this Research and Future Studies
The major limitation of this study was the lack of mechanistic data regarding how
TIMP C-terminal domain signaling altered proteolytic gene expression and activity, or cell
signaling indicators. Though my research is highly suggestive of a C-terminal signaling
function for TIMP-1 and -2, I did not investigate the specific receptors in X. laevis embryos
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associated with the observed changes in caspase-3 or proteolytic markers. While in vitro
studies have identified several cell surface binding partners for TIMP-1 and -2 C-terminal
domains, receptors and pathways vary with cell type. Indeed, there may be several cell
surface binding partners for TIMPs in X. laevis, which may vary not only between the
TIMPs, but also in different developing tissues and/or at different developmental stages.
As the research presented in this thesis was the first study of TIMP domain function
during development, I focused mainly on global changes within the whole embryo. I also
focused solely on organogenesis (stage 30 in development), at which time many
differentiation and remodeling events occur. A consequence of this approach, however, was
that I was only able to observe large-scale changes at one particular developmental time
point. A broader examination of TIMP domain function across other developmental stages,
such as neurulation and gastrulation, would improve our understanding of TIMP signaling, as
well as our understanding of how changes in gene expression may be correlated with changes
in protein levels and activities throughout development. Furthermore, in order to better
comprehend the mechanisms through which the N- and C-terminal TIMP domains manifest
their effects, a more detailed analysis of changes in the expression patterns of TIMPs, MMPs,
and various signaling markers across different tissue types throughout development is
warranted. This analysis would also provide an indication of whether different tissues have
distinct abilities to respond to TIMP C-terminal domain signals.
Future studies may use morpholinos to observe the consequences of TIMP
knockdown during X. laevis development, compared with overexpression of the full-length
constructs. Rescue experiments, whereby co-injecting MMP(s) along with TIMP N-terminal
domains would be useful in attempting to attenuate the effects of N-terminal domain
overexpression vs. C-terminal domain overexpression. Finally, co-localization and co-
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immunoprecipitation experiments should be used to identify cell surface binding partners for
the TIMP C-terminal domains. Examination of changes in additional signaling markers may
help link the individual TIMP C-terminal domains with specific changes in signaling
pathways in order to tease apart the mechanisms behind the opposing effects of T1C vs. T2C
overexpression.

5.4 Conclusions
Much of the current understanding regarding TIMP function during development has
been inferred from in vitro cell culture experiments using controlled, and therefore artificial
conditions. While the significance of these studies cannot be devalued as they have
considerably progressed the current understanding of ECM dynamics, studies focusing on in
vivo regulation of these molecules have been very limited in comparison. Although MMPs
have been fairly well characterized during development, the discovery of the C-terminal
domain functions of TIMPs has made understanding the interactions between these proteins
much more complicated (even in cell culture). The fact that TIMPs are now known to have
both pro- and anti-tumorigenic properties, has made TIMPs a hot topic for cancer research.
Consequently, investigation of TIMP C-terminal domain function has been carried out almost
exclusively using transformed cancer cell lines. The signaling pathways, however, that
TIMPs have been associated with in cancer progression are also important in the regulation
of development. The research presented in this thesis has been the first comprehensive
comparison of TIMP domain function in vivo. Additionally, I have provided the first
evidence that TIMPs have MMP-independent functions during development. Given the everincreasing importance of the TIMP C-terminal domains in disease, I believe that these
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proteins will also prove to be important regulators of developmental events as new and
interesting roles for the C-terminal domains are discovered.
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Appendix A:
Xenopus laevis TIMP-1 coding sequence (Accession number: KF018236)
1 atgttgtaccttgtggttgtgctggttctagggtgcctcagccag
46 gaggtgttggggtgcagctgtggacgtaggcacccccagtctgca
91 tactgcagtgcagattttgttattcgagggagattcattggaaag
136 acccagtacaagacagaagagcagggcagagtgaaatatgagatc
181 aaaactactaagatctttaaggcccctcaaggaatggacgacata
226 cagtttctcagcaccccatcaatggaaagcatgtgcggctacgag
271 cacgtcctctccaacaagagccaggccttcctcattacagggcat
316 gcggtgaatggtaacttggtaatcgaccagtgtaacttcattgtt
361 ccttgggcctcactaactaccgcccagaagaggggcttcgaggag
406 gtgtatcgcaaagcctgttcctgcaacatcgtcccctgctatggt
451 ggtagctgctccctggagtcggacagccagtgcctttggaccgat
496 gtactggtgcactggcaggagcccctcaatggctcccagtccaaa
541 tacatggcctgcgttgaccagggcaatggtctgtgcacatgggag
586 tcccagaagcccagcgtcatcgctgctaggaataaagaggcacag
631 tctgctgccacaacacaataa 651
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Appendix B:

Fig. B.1. Schematic X. laevis embryo at developmental stage 30. Adapted from Nieuwkoop
and Faber, 1956.
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Appendix C:

A

C

B

500 µm

500 µm

500 µm

Fig. C.1. Phenotypic effects of overexpression of TIMP C-terminal constructs. Following
injection, photographs were taken of representative embryos at stage 30. Microinjection of
TIMP-1 (A) and TIMP-2 (B) C-terminal domain constructs resulted in head and neural tube
defects. Overexpression of the TIMP-3 (C) C-terminal domain produced phenotypically
normal embryos. Actual size of all embryos is 1 mm in diameter. Images are of
representative embryos where results were consistent in at least 3 independent sets of
experiments, and a minimum of 100 embryos were injected and monitored for each replicate.
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Appendix D:
!!
CONT&
T2FL&
T2N&
T2C&
&& !!
CONT&
T3FL&
T3N&
T3C&

Ef#1α&
16.25!
15.99!
16.24!
14.81!

MMP#2&
24.52!
24.71!
25.38!
30.10!
!!

18.84!
18.83!
18.72!
18.55!

MMP#9&
25.09!
25.01!
27.03!
31.10!
!!

29.06!
33.54!
31.87!
31.42!

RECK&
26.28!
26.22!
26.90!
27.17!
!!

27.91!
32.03!
27.36!
28.28!

27.03!
28.15!
28.77!
26.68!

INTG&Beta1&
23.52!
23.35!
23.87!
24.33!
!!
26.08!
25.85!
25.61!
27.40!

Table D.1. Real-time PCR CT values for embryos injected with TIMP-2 and -3
constructs. Real-time PCR was used to measure the changes in transcript levels following
the injection of 4 ng of TIMP-2 full-length (T2FL), N-terminal (T2N), or C-terminal (T2C),
or TIMP-3 full-length (T3FL), N-terminal (T3N), or C-terminal (T3C) mRNA constructs into
X. laevis embryos at the one cell stage. The CT value represents the PCR cycle at which the
gene of interest passed a defined threshold. Changes in transcript levels were measured
relative to Ef-1α and normalized to CONT (control, uninjected) embryos. INTG Beta 1
represents β1 integrin. CT values are representative of one experiment.
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